Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1595334,Peak plasma clonidine concentrations,Peak plasma clonidine concentrations of 1.08 +/- 0.35 ng ml-1 (mean +/- s.d.) were reached between 5 and 10 min after injection.,Pharmacokinetics of clonidine after epidural administration in surgical patients. Lack of correlation between plasma concentration and analgesia and blood pressure changes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595334/),[ng] / [ml],1.08,8250,DB00575,Clonidine
,1595334,Plasma elimination half-life,Plasma elimination half-life was 829 +/- 157 min and plasma clearance was 177 +/- 28 ml min-1.,Pharmacokinetics of clonidine after epidural administration in surgical patients. Lack of correlation between plasma concentration and analgesia and blood pressure changes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595334/),min,829,8251,DB00575,Clonidine
,1595334,plasma clearance,Plasma elimination half-life was 829 +/- 157 min and plasma clearance was 177 +/- 28 ml min-1.,Pharmacokinetics of clonidine after epidural administration in surgical patients. Lack of correlation between plasma concentration and analgesia and blood pressure changes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595334/),[ml] / [min],177,8252,DB00575,Clonidine
,25776729,flow rate,"Chromatographic separation was performed on a Hypersil BDS C18 column (i.d. 2.1 × 50 mm, particle size 3μm) with a mobile phase of methanol-water (containing 0.1% formic acid; 60:40, v/v) at a flow rate of 200 μL/min.",Validation of a HPLC-ESI MS/MS method for the determination of clonidine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776729/),[μl] / [min],200,12790,DB00575,Clonidine
,25776729,extraction recovery,The extraction recovery was 72.53-85.25%.,Validation of a HPLC-ESI MS/MS method for the determination of clonidine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776729/),%,72.53-85.25,12791,DB00575,Clonidine
,11902803,Plasma,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,1.0,16784,DB00575,Clonidine
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,1.6,16785,DB00575,Clonidine
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,2.0,16786,DB00575,Clonidine
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,4.2,16787,DB00575,Clonidine
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,3.9,16788,DB00575,Clonidine
,11902803,interstitial,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,20.9,16789,DB00575,Clonidine
,11902803,cellular distribution volumes,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,4.2,16790,DB00575,Clonidine
,11902803,cellular distribution volumes,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,3.9,16791,DB00575,Clonidine
,11902803,cellular distribution volumes,"Plasma, interstitial and cellular distribution volumes for the solutes ranged from 1.0 mL (diclofenac) to 1.6 mL (salicylate), 2.0 mL (diclofenac) to 4.2 mL (water) and 3.9 mL (salicylate) to 20.9 mL (diclofenac), respectively.",Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),ml,20.9,16792,DB00575,Clonidine
,11902803,Permeability-surface area (PS),Permeability-surface area (PS) products calculated from plasma to interstitial fluid permeation clearances (CL(PI)) (range 0.02-0.40 mL s(-1)) and fractions of solute unbound in the perfusate were in the order: diclofenac > salicylate > clonidine > sucrose (from 41.8 to 0.10 mL s(-1)).,Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),[ml] / [s],0.02-0.40,16793,DB00575,Clonidine
,11902803,permeation clearances (CL(PI)),Permeability-surface area (PS) products calculated from plasma to interstitial fluid permeation clearances (CL(PI)) (range 0.02-0.40 mL s(-1)) and fractions of solute unbound in the perfusate were in the order: diclofenac > salicylate > clonidine > sucrose (from 41.8 to 0.10 mL s(-1)).,Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),[ml] / [s],0.02-0.40,16794,DB00575,Clonidine
,11902803,fractions,Permeability-surface area (PS) products calculated from plasma to interstitial fluid permeation clearances (CL(PI)) (range 0.02-0.40 mL s(-1)) and fractions of solute unbound in the perfusate were in the order: diclofenac > salicylate > clonidine > sucrose (from 41.8 to 0.10 mL s(-1)).,Distribution kinetics of solutes in the isolated in-situ perfused rat head using the multiple indicator dilution technique and a physiological two-barrier model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11902803/),[ml] / [s],41.8 to 0.10,16795,DB00575,Clonidine
,18821454,C(max),Pharmacokinetic analysis of plasma samples collected during study day 7 indicated that C(max) was 3242 +/- 917 ng/L.,"Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18821454/),[ng] / [l],3242,18632,DB00575,Clonidine
,1245090,half-life,The plasma concentration rose to a peak of 1.02 +/- 0.52 ng/ml (SD) at 90 min and fell with a mean half-life of 12.7 hr.,Clinical pharmacology and pharmacokinetics of clonidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1245090/),h,12.7,20940,DB00575,Clonidine
,2333412,area under the blood concentration-time curve,"The area under the blood concentration-time curve, following intravenous and nasal routes, was found to be 3.55 x 10(5) counts/g/min and 3.75 x 10(5) counts/g/min respectively.",Comparison of intravenous and nasal bioavailability of clonidine in rodents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333412/),[counts] / [g·min],3.55 x 10(5),22697,DB00575,Clonidine
,2333412,area under the blood concentration-time curve,"The area under the blood concentration-time curve, following intravenous and nasal routes, was found to be 3.55 x 10(5) counts/g/min and 3.75 x 10(5) counts/g/min respectively.",Comparison of intravenous and nasal bioavailability of clonidine in rodents. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333412/),[counts] / [g·min],3.75 x 10(5),22698,DB00575,Clonidine
,2333412,t1/2 beta,"The t1/2 beta, following intravenous and nasal administration, was found to be 8.8 hr and 8.0 hr respectively.",Comparison of intravenous and nasal bioavailability of clonidine in rodents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333412/),h,8.8,22699,DB00575,Clonidine
,2333412,t1/2 beta,"The t1/2 beta, following intravenous and nasal administration, was found to be 8.8 hr and 8.0 hr respectively.",Comparison of intravenous and nasal bioavailability of clonidine in rodents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2333412/),h,8.0,22700,DB00575,Clonidine
,32166831,clearance,A pooled analysis including data from 59 children indicated clearance of 14.4 L h-1 70 kg-1 and volume of distribution of 192.6 L 70 kg-1 .,Pharmacokinetics of an intravenous bolus dose of clonidine in children undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166831/),[l] / [70·h·kg],14.4,23679,DB00575,Clonidine
,32166831,volume of distribution,A pooled analysis including data from 59 children indicated clearance of 14.4 L h-1 70 kg-1 and volume of distribution of 192.6 L 70 kg-1 .,Pharmacokinetics of an intravenous bolus dose of clonidine in children undergoing surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32166831/),[l] / [70·kg],192.6,23680,DB00575,Clonidine
,4049475,detection limit,The detection limit of the assay is 2 pg based on a 200 microliters sample.,Radioimmunoassay for clonidine in human plasma and urine using a solid phase second antibody separation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049475/),pg,2,25037,DB00575,Clonidine
exceeds,3382465,recovery from blood,"Therefore, the method proves to be exceptionally selective and sensitive: a lower limit of detection of 10 pg/ml plasma is reached, the calibration curve is linear in the 25-1500 pg/ml range and the recovery from blood exceeds 90%.",Gas chromatographic/mass spectrometric determination of clonidine in body fluids. Application to pharmacokinetics. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3382465/),%,90,27438,DB00575,Clonidine
,9698954,Elimination half-lives,"Elimination half-lives of TZD in CSF were 15 min and 152 min, respectively.","Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698954/),min,15,28834,DB00575,Clonidine
,9698954,Elimination half-lives,"Elimination half-lives of TZD in CSF were 15 min and 152 min, respectively.","Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698954/),min,152,28835,DB00575,Clonidine
,9698954,Clearance,Clearance of TZD from lumbar CSF was 0.48 ml/min.,"Distribution, tolerability and tissue compatibility of intrathecal tizanidine in the sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698954/),[ml] / [min],0.48,28836,DB00575,Clonidine
,6127440,half-life,"3. The s 3341 plasma level rose to a maximum between the first and the third hours after ingestion and then declined, with a mean half-life of 14 hours.",[Pharmacokinetics of S 3341. Analysis by inhibition of the specific binding of 3H-clonidine]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6127440/),h,14,29794,DB00575,Clonidine
,6617726,absorption half-life,"The drug had a mean absorption half-life of 0.30 +/- 0.155 h following a mean lagtime of 0.361 +/- 0.118 h, and a mean terminal elimination half-life of 4.16 +/- 2.06 h.",Tizanidine--initial pharmacokinetic studies in patients with spasticity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617726/),h,0.30,32430,DB00575,Clonidine
,6617726,lagtime,"The drug had a mean absorption half-life of 0.30 +/- 0.155 h following a mean lagtime of 0.361 +/- 0.118 h, and a mean terminal elimination half-life of 4.16 +/- 2.06 h.",Tizanidine--initial pharmacokinetic studies in patients with spasticity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617726/),h,0.361,32431,DB00575,Clonidine
,6617726,terminal elimination half-life,"The drug had a mean absorption half-life of 0.30 +/- 0.155 h following a mean lagtime of 0.361 +/- 0.118 h, and a mean terminal elimination half-life of 4.16 +/- 2.06 h.",Tizanidine--initial pharmacokinetic studies in patients with spasticity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617726/),h,4.16,32432,DB00575,Clonidine
,29884231,trough concentration (C0),Median trough concentration (C0) at day 2 was 0.70 (0.47-0.96)μg/L.,The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29884231/),[μg] / [l],0.70,32587,DB00575,Clonidine
,29884231,C0,"At steady state, median C0 was 0.47 (0.36-0.76)μg/L, rising to Cmax 0.74 (0.56-0.95)μg/L 3 h post dose.",The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29884231/),[μg] / [l],0.47,32588,DB00575,Clonidine
,29884231,Cmax,"At steady state, median C0 was 0.47 (0.36-0.76)μg/L, rising to Cmax 0.74 (0.56-0.95)μg/L 3 h post dose.",The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29884231/),[μg] / [l],0.74,32589,DB00575,Clonidine
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,0.7-1.0,32863,DB00575,Clonidine
,1679616,concentration producing 50% inhibition (IC50),"The concentration producing 50% inhibition (IC50) of alfentanil (10 microM) oxidation was 0.7-1.0 and 2.8-4.0 microM for D-medetomidine and L-medetomidine, respectively.",Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1679616/),μM,2.8-4.0,32864,DB00575,Clonidine
,19640235,heart rate,"Two hours after admission, vital signs were blood pressure 259/107 mmHg and heart rate 140 beats/min.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),[beats] / [min],140,34374,DB00575,Clonidine
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,"1,530",34375,DB00575,Clonidine
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,865,34376,DB00575,Clonidine
,19640235,half-life,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),h,2,34377,DB00575,Clonidine
,18506682,run time,A run time of 2.5 min for each sample made it possible to analyze more than 250 human plasma samples per day.,Liquid chromatography tandem mass spectrometry method for the quantification of clonidine with LLOQ of 10 pg/mL in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18506682/),min,2.5,36657,DB00575,Clonidine
,8971830,Lumbar CSF levels,Lumbar CSF levels were in the range of 44 to 1230 ng/ml.,Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971830/),[ng] / [ml],44 to 1230,37003,DB00575,Clonidine
,10737913,cardiac outputs,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [min],5. 6,45827,DB00575,Clonidine
,10737913,cardiac outputs,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [min],5.1,45828,DB00575,Clonidine
,10737913,cardiac outputs,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [min],4.5,45829,DB00575,Clonidine
,10737913,clearances,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [h],40,45830,DB00575,Clonidine
,10737913,clearances,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [h],38,45831,DB00575,Clonidine
,10737913,clearances,"At dexmedetomidine concentrations of 0, 0.6, and 1.2 ng/mL, mean (SD) estimated cardiac outputs were 5. 6 (0.85), 5.1 (0.67), and 4.5 (0.83) L/min, and mean (SD) clearances were 40 (10), 38 (9.0), and 35 (8.5) L/h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),[l] / [h],35,45832,DB00575,Clonidine
,10737913,V(SS),"Dexmedetomidine V(SS) and elimination half-life were 72 (19) L and 1. 9 (0.62) h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),l,72,45833,DB00575,Clonidine
,10737913,elimination half-life,"Dexmedetomidine V(SS) and elimination half-life were 72 (19) L and 1. 9 (0.62) h, respectively.",Influence of cardiac output on dexmedetomidine pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10737913/),h,1. 9,45834,DB00575,Clonidine
,23380428,"peak plasma concentration, Cmax","The average bioavailability measures and pharmacokinetic parameters of the two tizanidine tablets were as follows: peak plasma concentration, Cmax, was 1.21 ± 0.84 ng/ml and 1.28 ± 1.11 ng/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[ng] / [ml],1.21,47473,DB00575,Clonidine
,23380428,"peak plasma concentration, Cmax","The average bioavailability measures and pharmacokinetic parameters of the two tizanidine tablets were as follows: peak plasma concentration, Cmax, was 1.21 ± 0.84 ng/ml and 1.28 ± 1.11 ng/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[ng] / [ml],1.28,47474,DB00575,Clonidine
,23380428,time to peak plasma concentrations tmax,"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,0.83,47475,DB00575,Clonidine
,23380428,time to peak plasma concentrations tmax,"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,1.01,47476,DB00575,Clonidine
,23380428,plasma half-life (t1/2),"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,1.20,47477,DB00575,Clonidine
,23380428,plasma half-life (t1/2),"The time to peak plasma concentrations tmax were 0.83 ± 0.43 and 1.01 ± 0.5 hours, while the plasma half-life (t1/2) values were 1.20 ± 0.84 and 1.29 ± 0.57 hours.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,1.29,47478,DB00575,Clonidine
,23380428,area under the plasma concentration-time profiles AUC0→last,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.53,47479,DB00575,Clonidine
,23380428,area under the plasma concentration-time profiles AUC0→last,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.46,47480,DB00575,Clonidine
,23380428,AUC0→∞were,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.81,47481,DB00575,Clonidine
,23380428,AUC0→∞were,"The area under the plasma concentration-time profiles AUC0→last were 2.53 ± 2.10 ng×h/ml and 2.46 ± 2.23 ng×h/ ml, whereas the AUC0→∞were 2.81 ± 2.27 ng×h/ml and 2.75 ± 2.37 ng×h/ml for Tizanidine PIC® and Sirdalud®, respectively.",Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),[h·ng] / [ml],2.75,47482,DB00575,Clonidine
,23380428,mean residence time (MRT),The mean residence time (MRT) values were 2.16 ± 0.693 hours and 2.33 ± 0.65 hours.,Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,2.16,47483,DB00575,Clonidine
,23380428,mean residence time (MRT),The mean residence time (MRT) values were 2.16 ± 0.693 hours and 2.33 ± 0.65 hours.,Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23380428/),h,2.33,47484,DB00575,Clonidine
,24680961,oral bioavailability,Tizanidine HCl is a skeletal muscle relaxant that suffers from extensive hepatic metabolism resulting in 34-40% oral bioavailability.,Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24680961/),%,34-40,52302,DB00575,Clonidine
,24680961,half-life,It also suffers from short half-life (2.1-4.2h) that necessitates frequent administration thus reducing patient compliance.,Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24680961/),h,2.1-4.2,52303,DB00575,Clonidine
,24680961,encapsulation efficiency,It provided encapsulation efficiency of 56.5% and controlled tizanidine release over 8h.,Chitosan lactate wafer as a platform for the buccal delivery of tizanidine HCl: in vitro and in vivo performance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24680961/),%,56.5,52304,DB00575,Clonidine
,7602472,apparent IC50,"At the effect compartment, the estimated apparent IC50 was 153.6 ng mL-1.",A pharmacokinetic-pharmacodynamic linking model for the alpha 2-adrenergic antagonism of idazoxan on clonidine-induced mydriasis in the rat. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602472/),[ng] / [ml],153.6,60032,DB00575,Clonidine
,7602472,clearance,"Values of clearance, volume of distribution and elimination half-life were 71.2 mL kg-1 min-1, 3134 mL kg-1 and 30.5 min, respectively.",A pharmacokinetic-pharmacodynamic linking model for the alpha 2-adrenergic antagonism of idazoxan on clonidine-induced mydriasis in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602472/),[ml] / [kg·min],71.2,60033,DB00575,Clonidine
,7602472,volume of distribution,"Values of clearance, volume of distribution and elimination half-life were 71.2 mL kg-1 min-1, 3134 mL kg-1 and 30.5 min, respectively.",A pharmacokinetic-pharmacodynamic linking model for the alpha 2-adrenergic antagonism of idazoxan on clonidine-induced mydriasis in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602472/),[ml] / [kg],3134,60034,DB00575,Clonidine
,7602472,elimination half-life,"Values of clearance, volume of distribution and elimination half-life were 71.2 mL kg-1 min-1, 3134 mL kg-1 and 30.5 min, respectively.",A pharmacokinetic-pharmacodynamic linking model for the alpha 2-adrenergic antagonism of idazoxan on clonidine-induced mydriasis in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7602472/),min,30.5,60035,DB00575,Clonidine
,27488910,Km,"In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a Km = 2.99 mM and Vmax = 179.5 nmol s-1 g-1.",Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27488910/),mM,2.99,60658,DB00575,Clonidine
,27488910,Vmax,"In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a Km = 2.99 mM and Vmax = 179.5 nmol s-1 g-1.",Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27488910/),[nM] / [g·s],179.5,60659,DB00575,Clonidine
,27488910,brain uptake clearance (Clup,"[11C]Diphenhydramine radiometabolites were not detected in the brain 15 min after injection, allowing for the reliable calculation of [11C]diphenhydramine brain uptake clearance (Clup = 0.99 ± 0.18 mL min-1 cm-3).",Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27488910/),[ml] / [(cm)^3·min],0.99,60660,DB00575,Clonidine
,21917532,flow rate,"The assay procedure involved chromatographic separation using a ZIC-HILIC SeQUANT column (250 mm × 4.6 mm, i.d., 5 μm) and a mobile phase of acetonitrile and acetate buffer (pH 3.4, 20mM) of ratio (=65:35, v/v) at a flow rate of 1.2 mL/min and detection wavelength of 201 nm.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),[ml] / [min],1.2,61099,DB00575,Clonidine
,21917532,Limit of detection,Limit of detection was 0.8 ng/mL at S/N of 3.,HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),[ng] / [ml],0.8,61100,DB00575,Clonidine
,21917532,S/N,Limit of detection was 0.8 ng/mL at S/N of 3.,HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),,3,61101,DB00575,Clonidine
,21917532,T(1/2),"Pharmacokinetic parameters estimated by using moment analysis were T(1/2) 198.3 ± 44.7 min, T(max) 28.3 ± 2.9 min and AUC(0-180) 15.6 ± 2.9(× 10(2))ngmin/mL.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),min,198.3,61102,DB00575,Clonidine
,21917532,T(max),"Pharmacokinetic parameters estimated by using moment analysis were T(1/2) 198.3 ± 44.7 min, T(max) 28.3 ± 2.9 min and AUC(0-180) 15.6 ± 2.9(× 10(2))ngmin/mL.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),min,28.3,61103,DB00575,Clonidine
,21917532,AUC(0-180),"Pharmacokinetic parameters estimated by using moment analysis were T(1/2) 198.3 ± 44.7 min, T(max) 28.3 ± 2.9 min and AUC(0-180) 15.6 ± 2.9(× 10(2))ngmin/mL.",HPLC-UV method development for fentanyl determination in rat plasma and its application to elucidate pharmacokinetic behavior after i.p. administration to rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21917532/),[ngmin] / [ml],15.6,61104,DB00575,Clonidine
,28156169,encapsulation efficiency,"It exhibited encapsulation efficiency of 52.39%, mean diameter of 150.33 nm, controlled drug release over 8 h and good permeation characteristics.","Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl: preparation, in vitro and in vivo performance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156169/),%,52.39,61544,DB00575,Clonidine
,28156169,t1/2,The pharmacokinetic study revealed that the transfersomal formulation successively enhanced the bioavailability of TIZ by about 2.18-fold and increased t1/2 to about 10 h as compared to oral solution.,"Nanotransfersomes-loaded thermosensitive in situ gel as a rectal delivery system of tizanidine HCl: preparation, in vitro and in vivo performance. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156169/),h,10,61545,DB00575,Clonidine
,8864326,Total body clearance,"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61881,DB00575,Clonidine
,8864326,apparent volume of distribution,"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61882,DB00575,Clonidine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61883,DB00575,Clonidine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],3.11,61884,DB00575,Clonidine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],4.48,61885,DB00575,Clonidine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],4.06,61886,DB00575,Clonidine
,17767627,clearance (CL),"Population parameter estimates (between subject variability) were clearance (CL) 14.6 (CV 35.1%) l x h(-1 )70 kg(-1), central volume of distribution (V1) 62.5 (71.1%) l 70 kg(-1), intercompartment clearance (Q) 157 (77.3%) l x h(-1) 70 kg(-1) and peripheral volume of distribution (V2) 119 (22.9%) l 70 kg(-1).",Clonidine disposition in children; a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),[l] / [70·h·kg],14.6,62857,DB00575,Clonidine
,17767627,central volume of distribution (V1),"Population parameter estimates (between subject variability) were clearance (CL) 14.6 (CV 35.1%) l x h(-1 )70 kg(-1), central volume of distribution (V1) 62.5 (71.1%) l 70 kg(-1), intercompartment clearance (Q) 157 (77.3%) l x h(-1) 70 kg(-1) and peripheral volume of distribution (V2) 119 (22.9%) l 70 kg(-1).",Clonidine disposition in children; a population analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),[l] / [70·kg],62.5,62858,DB00575,Clonidine
,17767627,intercompartment clearance (Q),"Population parameter estimates (between subject variability) were clearance (CL) 14.6 (CV 35.1%) l x h(-1 )70 kg(-1), central volume of distribution (V1) 62.5 (71.1%) l 70 kg(-1), intercompartment clearance (Q) 157 (77.3%) l x h(-1) 70 kg(-1) and peripheral volume of distribution (V2) 119 (22.9%) l 70 kg(-1).",Clonidine disposition in children; a population analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),[l] / [70·h·kg],157,62859,DB00575,Clonidine
,17767627,peripheral volume of distribution (V2),"Population parameter estimates (between subject variability) were clearance (CL) 14.6 (CV 35.1%) l x h(-1 )70 kg(-1), central volume of distribution (V1) 62.5 (71.1%) l 70 kg(-1), intercompartment clearance (Q) 157 (77.3%) l x h(-1) 70 kg(-1) and peripheral volume of distribution (V2) 119 (22.9%) l 70 kg(-1).",Clonidine disposition in children; a population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),[l] / [70·kg],119,62860,DB00575,Clonidine
,17767627,Clearance,Clearance at birth was 3.8 l x h(-1) 70 kg(-1) and matured with a half-time of 25.7 weeks to reach 82% adult rate by 1 year of age.,Clonidine disposition in children; a population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),[l] / [70·h·kg],3.8,62861,DB00575,Clonidine
,17767627,half-time,Clearance at birth was 3.8 l x h(-1) 70 kg(-1) and matured with a half-time of 25.7 weeks to reach 82% adult rate by 1 year of age.,Clonidine disposition in children; a population analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),weeks,25.7,62862,DB00575,Clonidine
,17767627,lag time,There was a lag time of 2.3 (CV 73.2%) min before absorption began in the rectum.,Clonidine disposition in children; a population analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),min,2.3,62863,DB00575,Clonidine
,17767627,F,The relative bioavailability of epidural and rectal clonidine was unity (F = 1).,Clonidine disposition in children; a population analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17767627/),,1,62864,DB00575,Clonidine
>,32150285,steady-state plasma concentration,"After modelling, doses to achieve a target steady-state plasma concentration of >1.5 μg/L were explored using stochastic Monte Carlo simulations for 1000 virtual patients.",Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),[μg] / [l],1.5,63632,DB00575,Clonidine
,32150285,CL,"Population PK parameters were: CL 17.1 (L/h), V1 124 (L/70 kg), intercompartmental CL 83.7 (L/h), and peripheral volume of distribution 178 (L), with 33.3% CV interindividual variability on CL and 66.8% CV interindividual variability on V1.",Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),[l] / [h],17.1,63633,DB00575,Clonidine
,32150285,V1,"Population PK parameters were: CL 17.1 (L/h), V1 124 (L/70 kg), intercompartmental CL 83.7 (L/h), and peripheral volume of distribution 178 (L), with 33.3% CV interindividual variability on CL and 66.8% CV interindividual variability on V1.",Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),[l] / [70·kg],124,63634,DB00575,Clonidine
,32150285,inter,"Population PK parameters were: CL 17.1 (L/h), V1 124 (L/70 kg), intercompartmental CL 83.7 (L/h), and peripheral volume of distribution 178 (L), with 33.3% CV interindividual variability on CL and 66.8% CV interindividual variability on V1.",Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),[l] / [h],83.7,63635,DB00575,Clonidine
,32150285,peripheral volume of distribution,"Population PK parameters were: CL 17.1 (L/h), V1 124 (L/70 kg), intercompartmental CL 83.7 (L/h), and peripheral volume of distribution 178 (L), with 33.3% CV interindividual variability on CL and 66.8% CV interindividual variability on V1.",Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),l,178,63636,DB00575,Clonidine
>,32150285,sedation concentrations,Simulations revealed that a maintenance dose of 1200 μg/d provides target sedation concentrations of >1.5 μg/L in 95% of the patients.,Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),[μg] / [l],1.5,63637,DB00575,Clonidine
>,32150285,sedation concentration,A dosing regimen of 1200 μg/d provided a target sedation concentration of >1.5 μg/L.,Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32150285/),μ,1.5,63638,DB00575,Clonidine
,2774269,time to maximal concentration (Tmax),"Dural transfer of epidurally administered clonidine was rapid and extensive: time to maximal concentration (Tmax) in CSF was 32 +/- 8 min, bioavailability in CSF was 14 +/- 4% of the administered dose, and maximal CSF concentrations following epidural administration (820 +/- 30 ng/ml) were three orders of magnitude greater than those following iv injection (0.71 +/- 0.06 ng/ml).","Pharmacokinetics and dynamics of intravenous, intrathecal, and epidural clonidine in sheep. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774269/),min,32,63844,DB00575,Clonidine
,2774269,bioavailability,"Dural transfer of epidurally administered clonidine was rapid and extensive: time to maximal concentration (Tmax) in CSF was 32 +/- 8 min, bioavailability in CSF was 14 +/- 4% of the administered dose, and maximal CSF concentrations following epidural administration (820 +/- 30 ng/ml) were three orders of magnitude greater than those following iv injection (0.71 +/- 0.06 ng/ml).","Pharmacokinetics and dynamics of intravenous, intrathecal, and epidural clonidine in sheep. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774269/),%,14,63845,DB00575,Clonidine
,2774269,maximal CSF concentrations,"Dural transfer of epidurally administered clonidine was rapid and extensive: time to maximal concentration (Tmax) in CSF was 32 +/- 8 min, bioavailability in CSF was 14 +/- 4% of the administered dose, and maximal CSF concentrations following epidural administration (820 +/- 30 ng/ml) were three orders of magnitude greater than those following iv injection (0.71 +/- 0.06 ng/ml).","Pharmacokinetics and dynamics of intravenous, intrathecal, and epidural clonidine in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774269/),[ng] / [ml],820,63846,DB00575,Clonidine
,2774269,maximal CSF concentrations,"Dural transfer of epidurally administered clonidine was rapid and extensive: time to maximal concentration (Tmax) in CSF was 32 +/- 8 min, bioavailability in CSF was 14 +/- 4% of the administered dose, and maximal CSF concentrations following epidural administration (820 +/- 30 ng/ml) were three orders of magnitude greater than those following iv injection (0.71 +/- 0.06 ng/ml).","Pharmacokinetics and dynamics of intravenous, intrathecal, and epidural clonidine in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774269/),[ng] / [ml],0.71,63847,DB00575,Clonidine
,2774269,Tmax,Systemic absorption of epidurally administered clonidine occurred rapidly: Tmax in plasma was 34 +/- 6 min and plasma concentrations were similar to those following iv injection at all time points beyond 20 min.,"Pharmacokinetics and dynamics of intravenous, intrathecal, and epidural clonidine in sheep. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774269/),min,34,63848,DB00575,Clonidine
,2774269,Elimination half-lives,Elimination half-lives from plasma were similar for all three routes of administration (81-95 min).,"Pharmacokinetics and dynamics of intravenous, intrathecal, and epidural clonidine in sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774269/),min,81-95,63849,DB00575,Clonidine
,7308242,t 1/2 alpha,"The blood plasma curves in man followed a multiexponential decline (t 1/2 alpha : 35 sec, t 1/2 beta : 44 min, t 1/2 gamma : 210 min).",Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308242/),s,35,68332,DB00575,Clonidine
,7308242,t 1/2 beta,"The blood plasma curves in man followed a multiexponential decline (t 1/2 alpha : 35 sec, t 1/2 beta : 44 min, t 1/2 gamma : 210 min).",Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308242/),min,44,68333,DB00575,Clonidine
,7308242,t 1/2 gamma,"The blood plasma curves in man followed a multiexponential decline (t 1/2 alpha : 35 sec, t 1/2 beta : 44 min, t 1/2 gamma : 210 min).",Pharmacokinetics and metabolism of 14C-labelled alinidine in man and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308242/),min,210,68334,DB00575,Clonidine
,25188774,half-life,"Clonidine levels could be demonstrated during the 24-h postoperative period, with an average half-life of 22 h.",Clonidine as an adjuvant to prolong local analgesia in conventional scleral buckle surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188774/),h,22,69632,DB00575,Clonidine
,24120717,Metabolic clearance,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],5.9,71230,DB00575,Clonidine
,24120717,Metabolic clearance,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],8.1 - 10.9,71231,DB00575,Clonidine
,24120717,renal clearances,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],0.040,71232,DB00575,Clonidine
,24120717,renal clearances,"Metabolic clearance of tizanidine was lower in Japanese than in Caucasian subjects (5.9 vs. 8.1 - 10.9 l/h/kg), although renal clearances were similar (0.040 vs. 0.047 - 0.055 l/h/kg).",Lower metabolic clearance of tizanidine in Japanese subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120717/),[l] / [h·kg],0.047 - 0.055,71233,DB00575,Clonidine
,18059052,Extraction recovery,"Extraction recovery was 84% for phenoprolamine hydrochloride at a concentration level of 200 ng/mL, and 76% for clonidine at 200 ng/mL.",A simple and sensitive HPLC method for quantitation of low phenoprolamine hydrochloride concentrations in human plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059052/),%,84,72707,DB00575,Clonidine
,18059052,Extraction recovery,"Extraction recovery was 84% for phenoprolamine hydrochloride at a concentration level of 200 ng/mL, and 76% for clonidine at 200 ng/mL.",A simple and sensitive HPLC method for quantitation of low phenoprolamine hydrochloride concentrations in human plasma and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059052/),%,76,72708,DB00575,Clonidine
,6832197,complete,1. The complete bioavailability of clonidine and its elimination half-life (20 to 25.5 h) remained constant after single and multiple doses.,New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832197/),h,20 to 25.5,78070,DB00575,Clonidine
,6832197,elimination half-life,1. The complete bioavailability of clonidine and its elimination half-life (20 to 25.5 h) remained constant after single and multiple doses.,New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832197/),h,20 to 25.5,78071,DB00575,Clonidine
,32911847,flow rate,"The mobile phase composition was a mixture of 0.1% diethylamine/acetonitrile (70:30, v/v) at pH 8 in an isocratic mode at flow rate was 1.0 mL/min.",Development and Validation of an HPLC-UV Detection Assay for the Determination of Clonidine in Mouse Plasma and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32911847/),[ml] / [min],1.0,81824,DB00575,Clonidine
,2723120,maximal plasma concentrations,Following a single dose of clonidine maximal plasma concentrations of 0.34 +/- 0.06 ng/ml were achieved after 3.6 +/- 1.2 hours.,Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723120/),[ng] / [ml],0.34,83315,DB00575,Clonidine
,2723120,maximal concentration,"After 5 days of repetitive dosing the maximal concentration was significantly higher, 0.66 +/- 0.06 ng/ml and remained so throughout chronic therapy (P = 0.018).",Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723120/),[ng] / [ml],0.66,83316,DB00575,Clonidine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,1.5,84231,DB00575,Clonidine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,4,84232,DB00575,Clonidine
,658114,absorption half-life,The plasma concentration of clonidine rose to a peak of 1.17 +/- 0.12 ng/ml at about 2 h: the absorption half-life was 0.6 +/- 0.2 h.,Pharmacokinetics and side-effects of clonidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/658114/),h,0.6,85125,DB00575,Clonidine
,658114,half-life,Elimination followed first order kinetics with a half-life of 7.7 +/- 2.0 h.,Pharmacokinetics and side-effects of clonidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658114/),h,7.7,85126,DB00575,Clonidine
,658114,steady state serum level,During continuous administration of clonidine (75 microgram t.i.d.) for one week a steady state serum level of 0.30-0.35 ng/ml was achieved.,Pharmacokinetics and side-effects of clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658114/),[ng] / [ml],0.30-0.35,85127,DB00575,Clonidine
,658114,half-life,"After cessation of dosing, the serum level declined with a half-life of 7.5 +/- 1.5 h.",Pharmacokinetics and side-effects of clonidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/658114/),h,7.5,85128,DB00575,Clonidine
,17617289,C(max),"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),[ng] / [ml],2.7,91385,DB00575,Clonidine
,17617289,C(max),"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),[ng] / [ml],4.0,91386,DB00575,Clonidine
,17617289,TmaX,"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),h,2.6,91387,DB00575,Clonidine
,17617289,TmaX,"The peak exposure, as measured by mean natural logarithm-transformed C(max) values, was significantly lower with the capsule compared with the tablet (2.7 vs 4.0 ng/mL; P < 0.019), and mean TmaX was significantly longer (2.6 vs 1.2 hours; P < 0.001).","Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17617289/),h,1.2,91388,DB00575,Clonidine
,1831005,relative extents of absorption (Frel),"The mean +/- SD relative extents of absorption (Frel) of clonidine following dermal pretreatment with hydrocortisone and magnesium-aluminum hydroxide in respect to the transdermal patch alone were 94.84 +/- 45.69% and 97.65 +/- 59.65%, respectively.",Skin pretreatment and the use of transdermal clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831005/),%,94.84,92589,DB00575,Clonidine
,1831005,relative extents of absorption (Frel),"The mean +/- SD relative extents of absorption (Frel) of clonidine following dermal pretreatment with hydrocortisone and magnesium-aluminum hydroxide in respect to the transdermal patch alone were 94.84 +/- 45.69% and 97.65 +/- 59.65%, respectively.",Skin pretreatment and the use of transdermal clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1831005/),%,97.65,92590,DB00575,Clonidine
,7614654,maximal concentration in serum (Cmax,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [ml],2.553,93265,DB00575,Clonidine
,7614654,maximal concentration in serum (Cmax,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),ml01·μg,0.962,93266,DB00575,Clonidine
,7614654,area under the concentration curve (AUC,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [h·ml],3.530,93267,DB00575,Clonidine
,7614654,area under the concentration curve (AUC,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [h·ml],1.755,93268,DB00575,Clonidine
,7614654,Clearance (Cl),"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [ml],0.603,93269,DB00575,Clonidine
,7614654,Clearance (Cl),"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [ml],1.264,93270,DB00575,Clonidine
,7614654,ratio,"The ratio of AUC PPX/AUC bupivacaine (which may partially indicate the rate of metabolism) was lower in presence of clonidine (0.220 +/- 0.019 against 0.425 +/- 0.033 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),,0.220,93271,DB00575,Clonidine
,7614654,ratio,"The ratio of AUC PPX/AUC bupivacaine (which may partially indicate the rate of metabolism) was lower in presence of clonidine (0.220 +/- 0.019 against 0.425 +/- 0.033 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),,0.425,93272,DB00575,Clonidine
,8541437,EC50,Calculation of the EC50 resulted in a value of 25.5 +/- 2.0 microM.,[Clonidine increases the anesthetic effectiveness of thiopental]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541437/),μM,25.5,94637,DB00575,Clonidine
,8541437,EC50,In presence of clonidine thiopental exhibited a left shift of the concentration-response curve with an EC50 of 12.3 +/- 1.6 microM (Slope: 2.75 +/- 0.3).,[Clonidine increases the anesthetic effectiveness of thiopental]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541437/),μM,12.3,94638,DB00575,Clonidine
,8541437,Slope,In presence of clonidine thiopental exhibited a left shift of the concentration-response curve with an EC50 of 12.3 +/- 1.6 microM (Slope: 2.75 +/- 0.3).,[Clonidine increases the anesthetic effectiveness of thiopental]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541437/),,2.75,94639,DB00575,Clonidine
above,31373752,target plasma concentration,A target plasma concentration of above 2 µg/L was proposed.,Optimizing clonidine dosage for sedation in mechanically ventilated children: A pharmacokinetic simulation study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31373752/),[μg] / [l],2,98380,DB00575,Clonidine
,8439023,minimum effective CSF clonidine concentration,Extrapolation of CSF clonidine pharmacokinetics suggests the minimum effective CSF clonidine concentration for postoperative pain relief is 76 +/- 15 ng/ml.,Hemodynamic and analgesic actions of epidurally administered clonidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439023/),[ng] / [ml],76,101547,DB00575,Clonidine
,1408302,maximum CSF concentration,These analyses revealed a mean maximum CSF concentration of 228 ng/ml whereas the mean plasma concentration at all time points was less than 0.7 ng/ml.,Cerebrospinal fluid kinetics of epidural clonidine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1408302/),[ng] / [ml],228,101886,DB00575,Clonidine
less,1408302,plasma concentration,These analyses revealed a mean maximum CSF concentration of 228 ng/ml whereas the mean plasma concentration at all time points was less than 0.7 ng/ml.,Cerebrospinal fluid kinetics of epidural clonidine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1408302/),[ng] / [ml],0.7,101887,DB00575,Clonidine
,1408302,elimination half-life,"The elimination half-life of epidural clonidine was 66 +/- 2 min, while the absorption half-life was 31 +/- 7 min, Tmax was 60 +/- 7 min and Cmax was 228 +/- 56 ng/ml.",Cerebrospinal fluid kinetics of epidural clonidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1408302/),min,66,101888,DB00575,Clonidine
,1408302,absorption half-life,"The elimination half-life of epidural clonidine was 66 +/- 2 min, while the absorption half-life was 31 +/- 7 min, Tmax was 60 +/- 7 min and Cmax was 228 +/- 56 ng/ml.",Cerebrospinal fluid kinetics of epidural clonidine in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1408302/),min,31,101889,DB00575,Clonidine
,1408302,Tmax,"The elimination half-life of epidural clonidine was 66 +/- 2 min, while the absorption half-life was 31 +/- 7 min, Tmax was 60 +/- 7 min and Cmax was 228 +/- 56 ng/ml.",Cerebrospinal fluid kinetics of epidural clonidine in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1408302/),min,60,101890,DB00575,Clonidine
,1408302,Cmax,"The elimination half-life of epidural clonidine was 66 +/- 2 min, while the absorption half-life was 31 +/- 7 min, Tmax was 60 +/- 7 min and Cmax was 228 +/- 56 ng/ml.",Cerebrospinal fluid kinetics of epidural clonidine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1408302/),[ng] / [ml],228,101891,DB00575,Clonidine
,19637105,half-life,The average half-life obtained from all profiles was 12.1 +/- 6.3 hr.,Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19637105/),h,12.1,103143,DB00575,Clonidine
,19637105,Fe,Fe values ranged between .01% and 34% with high variability within the same dosing regimen.,Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19637105/),%,.01,103144,DB00575,Clonidine
,19637105,Fe,Fe values ranged between .01% and 34% with high variability within the same dosing regimen.,Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19637105/),%,34,103145,DB00575,Clonidine
,1888048,Onset of analgesia,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,13,103224,DB00575,Clonidine
,1888048,Onset of analgesia,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,13,103225,DB00575,Clonidine
,1888048,duration,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,543,103226,DB00575,Clonidine
,1888048,duration,"Onset of analgesia was similar in the two groups of patients (13 +/- 6 and 13 +/- 3 min, respectively, after injection), but duration was more than doubled in the patients receiving clonidine (543 +/- 183 vs. 250 +/- 64 min).",Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),min,250,103227,DB00575,Clonidine
,1888048,Peak plasma fentanyl concentrations (Fmax),Peak plasma fentanyl concentrations (Fmax) and the time to reach Cmax (Tmax) were comparable in the two groups (0.29 +/- 0.15 ng.,Effect of epidural clonidine on analgesia and pharmacokinetics of epidural fentanyl in postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888048/),ng,0.29,103228,DB00575,Clonidine
,33615926,Tmax,The Tmax of the CH sustained-release suspension was delayed from 2 h to 5 h compared with the CH ordinary tablets.,Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),h,2,103527,DB00575,Clonidine
,33615926,Tmax,The Tmax of the CH sustained-release suspension was delayed from 2 h to 5 h compared with the CH ordinary tablets.,Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),h,5,103528,DB00575,Clonidine
,33615926,Cmax,"Similarly, the Cmax was reduced from 32.138 µg·mL-1 to 18.150 µg·mL-1 with the concentration-time curve being more gentle compared with the commercially CH ordinary tablets.",Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),[μg] / [ml],32.138,103529,DB00575,Clonidine
,33615926,Cmax,"Similarly, the Cmax was reduced from 32.138 µg·mL-1 to 18.150 µg·mL-1 with the concentration-time curve being more gentle compared with the commercially CH ordinary tablets.",Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),[μg] / [ml],18.150,103530,DB00575,Clonidine
,33615926,relative bioavailability,"After oral administration, the relative bioavailability of CH sustained-release suspension (AUC0-24 of 137.703 µg·h·mL-1) to its CH ordinary tablets (AUC0-24 of 123.337 µg·h·mL-1) was 111.65%.",Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),[h·μg] / [ml],137.703,103531,DB00575,Clonidine
,33615926,AUC0-24,"After oral administration, the relative bioavailability of CH sustained-release suspension (AUC0-24 of 137.703 µg·h·mL-1) to its CH ordinary tablets (AUC0-24 of 123.337 µg·h·mL-1) was 111.65%.",Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),[h·μg] / [ml],137.703,103532,DB00575,Clonidine
,33615926,AUC0-24,"After oral administration, the relative bioavailability of CH sustained-release suspension (AUC0-24 of 137.703 µg·h·mL-1) to its CH ordinary tablets (AUC0-24 of 123.337 µg·h·mL-1) was 111.65%.",Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),[h·μg] / [ml],123.337,103533,DB00575,Clonidine
,33615926,AUC0-24,"After oral administration, the relative bioavailability of CH sustained-release suspension (AUC0-24 of 137.703 µg·h·mL-1) to its CH ordinary tablets (AUC0-24 of 123.337 µg·h·mL-1) was 111.65%.",Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug-resin suspension as a sustained-release formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33615926/),%,111.65,103534,DB00575,Clonidine
,19143953,maximum plasma concentration,"A total of 95% confidence intervals for maximum plasma concentration and time to achieve maximum plasma concentration were 0.4-0.6 ng x ml(-1) and 1.4-3.0 h, respectively.",Absorption pharmacokinetics of clonidine nasal drops in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19143953/),[ng] / [ml],0.4-0.6,111595,DB00575,Clonidine
,19143953,time to achieve maximum plasma concentration,"A total of 95% confidence intervals for maximum plasma concentration and time to achieve maximum plasma concentration were 0.4-0.6 ng x ml(-1) and 1.4-3.0 h, respectively.",Absorption pharmacokinetics of clonidine nasal drops in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19143953/),h,1.4-3.0,111596,DB00575,Clonidine
,4039184,bioavailability,Excellent bioavailability (0.87-0.96) was obtained in all 12 subjects for each of the formulations.,Pharmacokinetics of oral sustained release clonidine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039184/),,0.87-0.96,116853,DB00575,Clonidine
,4039184,final phase half-life,The intravenous pharmacokinetics of clonidine after a 0.2 mg infusion followed a tri-exponential decline with a final phase half-life of 13.6 h (harmonic mean).,Pharmacokinetics of oral sustained release clonidine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039184/),h,13.6,116854,DB00575,Clonidine
,4039184,renal clearance,Following the intravenous infusion 42.3% of the dose was excreted unchanged in the urine with a renal clearance of 10.05 +/- 0.65 1/h (167 ml/min).,Pharmacokinetics of oral sustained release clonidine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039184/),[1] / [h],10.05,116855,DB00575,Clonidine
,24085590,relative bioavailability,"The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),,1.29,122503,DB00575,Clonidine
,24085590,relative bioavailability,"The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),,1.93,122504,DB00575,Clonidine
,24085590,relative bioavailability,"The relative bioavailability of the different dosages of intranasal formulation were 1.29, 1.93, and 4.23 for 1, 2, and 4 mg intranasal administration, respectively.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),,4.23,122505,DB00575,Clonidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,0.99,122506,DB00575,Clonidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,0.43,122507,DB00575,Clonidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,0.63,122508,DB00575,Clonidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,1.13,122509,DB00575,Clonidine
,24085590,time to C(max) (t(max)),"The mean time to C(max) (t(max)) was 0.99, 0.43, and 0.63 h for 1, 2, and 4 mg intranasal administration, respectively, whereas it was 1.13 and 1.30 h for the two series of 4 mg tizanidine oral tablets.","Pharmacokinetic characterization of tizanidine nasal spray, a novel intranasal delivery method for the treatment of skeletal muscle spasm. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24085590/),h,1.30,122510,DB00575,Clonidine
,3447935,bioavailability,"Tizanidine was rapidly and almost completely absorbed from the gastrointestinal tract, although the estimated bioavailability was only 21% due to extensive first-pass metabolism.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),%,21,122983,DB00575,Clonidine
,3447935,terminal half-lives,"The terminal half-lives of tizanidine and radioactivity were ca 3 hr and 61 hr, respectively, and 76%-77% of the administered radioactivity was recovered within 120 hr.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),h,3,122984,DB00575,Clonidine
,3447935,terminal half-lives,"The terminal half-lives of tizanidine and radioactivity were ca 3 hr and 61 hr, respectively, and 76%-77% of the administered radioactivity was recovered within 120 hr.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),h,61,122985,DB00575,Clonidine
,3447935,effective half-life,"The degree of accumulation of radioactivity, unlike that of parent drug, was inconsistent with the terminal half-life, but instead implied a shorter effective half-life of ca. 16 hr.",Pharmacokinetics of orally administered tizanidine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447935/),h,16,122986,DB00575,Clonidine
,19585373,recovery,"The cumulative (14)C-uracil recovery (%) at 168 h was 92.3, 6.3, or 0.5%, from expired gases, urine, and feces, respectively.",Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19585373/),%,92.3,123096,DB00575,Clonidine
,19585373,recovery,"The cumulative (14)C-uracil recovery (%) at 168 h was 92.3, 6.3, or 0.5%, from expired gases, urine, and feces, respectively.",Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19585373/),%,6.3,123097,DB00575,Clonidine
,19585373,recovery,"The cumulative (14)C-uracil recovery (%) at 168 h was 92.3, 6.3, or 0.5%, from expired gases, urine, and feces, respectively.",Desirable pharmacokinetic properties of (13)C-uracil as a breath test probe of gastric emptying in comparison with (13)C-acetate and (13)C-octanoate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19585373/),%,0.5,123098,DB00575,Clonidine
,4028622,steady-state plasma concentrations,"The mean steady-state plasma concentrations with 3.5, 7.0, and 10.5 cm2 systems were 0.39, 0.84, and 1.12 ng/ml, respectively.",Pharmacokinetics of transdermally delivered clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028622/),[ng] / [ml],0.39,127122,DB00575,Clonidine
,4028622,steady-state plasma concentrations,"The mean steady-state plasma concentrations with 3.5, 7.0, and 10.5 cm2 systems were 0.39, 0.84, and 1.12 ng/ml, respectively.",Pharmacokinetics of transdermally delivered clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028622/),[ng] / [ml],0.84,127123,DB00575,Clonidine
,4028622,steady-state plasma concentrations,"The mean steady-state plasma concentrations with 3.5, 7.0, and 10.5 cm2 systems were 0.39, 0.84, and 1.12 ng/ml, respectively.",Pharmacokinetics of transdermally delivered clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028622/),[ng] / [ml],1.12,127124,DB00575,Clonidine
,6626441,Plasma concentrations,Plasma concentrations of alinidine reached a maximum of 163.6 +/- 10.0 ng/ml 2 h after alinidine administration on day 1 and during chronic administration similar concentrations were achieved.,An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626441/),[ng] / [ml],163.6,130460,DB00575,Clonidine
,6626441,plasma concentrations,"Clonidine plasma concentrations reached 0.3 +/- 0.11 ng/ml 6 h after alinidine 40 mg on day 1, and during chronic administration of alinidine, increased to a steady state on day 5 with trough and 2 h values of 0.73 +/- 0.15 and 0.86 +/- 0.14 ng/ml respectively.",An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626441/),[ng] / [ml],0.3,130461,DB00575,Clonidine
,6626441,trough,"Clonidine plasma concentrations reached 0.3 +/- 0.11 ng/ml 6 h after alinidine 40 mg on day 1, and during chronic administration of alinidine, increased to a steady state on day 5 with trough and 2 h values of 0.73 +/- 0.15 and 0.86 +/- 0.14 ng/ml respectively.",An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626441/),[ng] / [ml],0.73,130462,DB00575,Clonidine
,6626441,2 h,"Clonidine plasma concentrations reached 0.3 +/- 0.11 ng/ml 6 h after alinidine 40 mg on day 1, and during chronic administration of alinidine, increased to a steady state on day 5 with trough and 2 h values of 0.73 +/- 0.15 and 0.86 +/- 0.14 ng/ml respectively.",An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626441/),[ng] / [ml],0.86,130463,DB00575,Clonidine
,6626441,maximum plasma concentration,"After the first dose of clonidine on day 1, the maximum plasma concentration of clonidine was 0.32 +/- 0.1 ng/ml at 4 h, during chronic administration clonidine plasma concentration rose to 1.04 +/- 0.14 ng/ml 2 h after a dose on day 5.",An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626441/),[ng] / [ml],0.32,130464,DB00575,Clonidine
,6626441,plasma concentration,"After the first dose of clonidine on day 1, the maximum plasma concentration of clonidine was 0.32 +/- 0.1 ng/ml at 4 h, during chronic administration clonidine plasma concentration rose to 1.04 +/- 0.14 ng/ml 2 h after a dose on day 5.",An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626441/),[ng] / [ml],1.04,130465,DB00575,Clonidine
,8223840,terminal half-life,After a mean period of treatment of 9.2 (range 3 to 26) days and a mean dose of 0.72 (range 0.29 to 2.37) mg per day of clonidine the mean terminal half-life was 15.8 (range 9.9 to 23) h (n = 7).,The pharmacokinetics of clonidine in high dosage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,15.8,131442,DB00575,Clonidine
,8223840,distribution half-life,"The pharmacokinetics of clonidine were described by two exponentials, with a distribution half-life of 1.2 h and a terminal half-life of 14.6 h.",The pharmacokinetics of clonidine in high dosage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,1.2,131443,DB00575,Clonidine
,8223840,terminal half-life,"The pharmacokinetics of clonidine were described by two exponentials, with a distribution half-life of 1.2 h and a terminal half-life of 14.6 h.",The pharmacokinetics of clonidine in high dosage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,14.6,131444,DB00575,Clonidine
,8223840,terminal half-life,After a mean period of 8.3 (range 2 to 15) days and a mean dose of 0.62 (range 0.15 to 1.82) mg per day the terminal half-life in these four patients was 15.6 (range 14.0 to 17.9) h.,The pharmacokinetics of clonidine in high dosage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223840/),h,15.6,131445,DB00575,Clonidine
,19789372,peak plasma concentration,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[ng] / [ml],1.8,132457,DB00575,Clonidine
,19789372,peak plasma concentration,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[ng] / [ml],5.3,132458,DB00575,Clonidine
,19789372,area under the curve,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[h·ng] / [ml],4.5,132459,DB00575,Clonidine
,19789372,area under the curve,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),[h·ng] / [ml],15.4,132460,DB00575,Clonidine
,19789372,half-life,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),h,1.3,132461,DB00575,Clonidine
,19789372,half-life,"Compared with tizanidine alone, mexiletine coadministration increased the peak plasma concentration (1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL), area under the curve (4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL), and the half-life (1.3 +/- 0.2 vs 1.8 +/- 0.7 h) of tizanidine, respectively (P < .05).","Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19789372/),h,1.8,132462,DB00575,Clonidine
,7318879,t1/2 alpha,"The half lives of the distribution and elimination phases were t1/2 alpha: 36-41s, t1/2 beta: 9.9-11.1 min and t 1/2 gamma: 2.7-3.8h.",Proof of the linearity of the pharmacokinetics of alinidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318879/),s,36-41,132549,DB00575,Clonidine
,7318879,t1/2 beta,"The half lives of the distribution and elimination phases were t1/2 alpha: 36-41s, t1/2 beta: 9.9-11.1 min and t 1/2 gamma: 2.7-3.8h.",Proof of the linearity of the pharmacokinetics of alinidine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318879/),min,9.9-11.1,132550,DB00575,Clonidine
,7318879,t 1/2 gamma,"The half lives of the distribution and elimination phases were t1/2 alpha: 36-41s, t1/2 beta: 9.9-11.1 min and t 1/2 gamma: 2.7-3.8h.",Proof of the linearity of the pharmacokinetics of alinidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318879/),h,2.7-3.8,132551,DB00575,Clonidine
,7318879,tau,"Following a lag period (tau =0.19-0.22h), the peak plasma concentration was reached 0.6-1.2h after oral administration.",Proof of the linearity of the pharmacokinetics of alinidine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318879/),h,0.19-0.22,132552,DB00575,Clonidine
,7318879,bioavailable,Oral alinidine was 100% bioavailable.,Proof of the linearity of the pharmacokinetics of alinidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7318879/),%,100,132553,DB00575,Clonidine
,17062304,T(max),The median T(max) increased significantly from 1.41 to 3.0 hours (P < 0.001).,Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062304/),h,1.41,135858,DB00575,Clonidine
,17062304,T(max),The median T(max) increased significantly from 1.41 to 3.0 hours (P < 0.001).,Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17062304/),h,3.0,135859,DB00575,Clonidine
,6822136,terminal elimination half-life,The following findings were established: (1) The terminal elimination half-life of clonidine was 20 to 25 hours.,New aspects of the clinical pharmacology of clonidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822136/),h,20 to 25,146562,DB00575,Clonidine
,6822136,bioavailable,(4) Clonidine was 100 percent bioavailable in tablets and Perlongets.,New aspects of the clinical pharmacology of clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6822136/),%,100,146563,DB00575,Clonidine
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,51.2,152868,DB00575,Clonidine
,8544280,clinical duration,"The clinical duration of vecuronium, defined as recovery to 25% of the control first twitch in the train-of-four sequence, was significantly longer in the clonidine group (51.2 +/- 7.5 minutes compared with 40.5 +/- 5.1 minutes in the control group, P < 0.01).",[The effect of clonidine on the duration of vecuronium-induced neuromuscular blockade in humans]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8544280/),min,40.5,152869,DB00575,Clonidine
,9542557,Cmax,"Cmax and Tmax values of clonidine were found to be within the 0.45-0.77 ng/mL and 48-193 min range, respectively.",Plasma levels of clonidine following epidural bolus injection in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),[ng] / [ml],0.45-0.77,153629,DB00575,Clonidine
,9542557,Tmax,"Cmax and Tmax values of clonidine were found to be within the 0.45-0.77 ng/mL and 48-193 min range, respectively.",Plasma levels of clonidine following epidural bolus injection in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),min,48-193,153630,DB00575,Clonidine
,9542557,time to absorb 95%,The time to absorb 95% of the clonidine dose from the epidural space into plasma varied between 36 min and 7.6 h.,Plasma levels of clonidine following epidural bolus injection in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),min,36,153631,DB00575,Clonidine
,9542557,time to absorb 95%,The time to absorb 95% of the clonidine dose from the epidural space into plasma varied between 36 min and 7.6 h.,Plasma levels of clonidine following epidural bolus injection in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),h,7.6,153632,DB00575,Clonidine
,16011885,m/z,LC-ESI-MS was performed in the selected-ion monitoring (SIM) mode using target ions at m/z: 242.2 for moxonidine and m/z: 230.1 for the IS.,Determination of moxonidine in human plasma by liquid chromatography-electrospray ionisation-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16011885/),,242.2,153984,DB00575,Clonidine
,16011885,m/z,LC-ESI-MS was performed in the selected-ion monitoring (SIM) mode using target ions at m/z: 242.2 for moxonidine and m/z: 230.1 for the IS.,Determination of moxonidine in human plasma by liquid chromatography-electrospray ionisation-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16011885/),,230.1,153985,DB00575,Clonidine
,3746638,corneal absorption rate constant ka,"The calculated values are: corneal absorption rate constant ka, 0.00139 min-1, aqueous humor elimination rate constant k10, 0.0658 min-1; mean residence time MRTd, 35.6 min; apparent steady-state volume of distribution Vss, 0.530 ml; and ocular clearance Qe, 14.9 microliter/min.",Ocular pharmacokinetic models of clonidine-3H hydrochloride. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746638/),1/[min],0.00139,154015,DB00575,Clonidine
,3746638,mean residence time MRTd,"The calculated values are: corneal absorption rate constant ka, 0.00139 min-1, aqueous humor elimination rate constant k10, 0.0658 min-1; mean residence time MRTd, 35.6 min; apparent steady-state volume of distribution Vss, 0.530 ml; and ocular clearance Qe, 14.9 microliter/min.",Ocular pharmacokinetic models of clonidine-3H hydrochloride. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746638/),min,35.6,154016,DB00575,Clonidine
,3746638,apparent steady-state volume of distribution Vss,"The calculated values are: corneal absorption rate constant ka, 0.00139 min-1, aqueous humor elimination rate constant k10, 0.0658 min-1; mean residence time MRTd, 35.6 min; apparent steady-state volume of distribution Vss, 0.530 ml; and ocular clearance Qe, 14.9 microliter/min.",Ocular pharmacokinetic models of clonidine-3H hydrochloride. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746638/),ml,0.530,154017,DB00575,Clonidine
,3746638,ocular clearance Qe,"The calculated values are: corneal absorption rate constant ka, 0.00139 min-1, aqueous humor elimination rate constant k10, 0.0658 min-1; mean residence time MRTd, 35.6 min; apparent steady-state volume of distribution Vss, 0.530 ml; and ocular clearance Qe, 14.9 microliter/min.",Ocular pharmacokinetic models of clonidine-3H hydrochloride. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746638/),[μl] / [min],14.9,154018,DB00575,Clonidine
,3746638,fraction absorbed,The fraction absorbed from the single instillation is estimated as 0.0163.,Ocular pharmacokinetic models of clonidine-3H hydrochloride. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3746638/),,0.0163,154019,DB00575,Clonidine
,25080430,Cmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[ng] / [ml],0.15 to 1.55,154363,DB00575,Clonidine
,25080430,Cmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[ng] / [ml],0.73,154364,DB00575,Clonidine
,25080430,Tmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),min,12 to 478,154365,DB00575,Clonidine
,25080430,Tmax,"Enteral absorption showed considerable inter-individual variability, with clonidine Cmax ranging from 0.15 to 1.55 ng ml(-1) (median 0.73), and Tmax from 12 to 478 min (median 190).",Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),min,190,154366,DB00575,Clonidine
,25080430,clearance,Population pharmacokinetic parameter estimation yielded results similar to previous paediatric studies: clearance 13.7 litre h(-1) 70 kg(-1) and Vd 181 litre 70 kg(-1).,Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[l] / [70·h·kg],13.7,154367,DB00575,Clonidine
,25080430,Vd,Population pharmacokinetic parameter estimation yielded results similar to previous paediatric studies: clearance 13.7 litre h(-1) 70 kg(-1) and Vd 181 litre 70 kg(-1).,Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25080430/),[l] / [70·kg],181,154368,DB00575,Clonidine
,18197403,K(i) (inhibitor constant),Celecoxib was found to be a moderately potent competitive inhibitor of CYP1A2 in vitro with a K(i) (inhibitor constant) of 25.4 microM.,Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197403/),μM,25.4,155529,DB00575,Clonidine
,7120048,half-lives,The rate of disappearance of clonidine from most tissues was best described by a monoexponential curve with half-lives of 30 to 120 min.,Tissue pharmacokinetics of clonidine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120048/),min,30 to 120,155988,DB00575,Clonidine
,3816873,half-lives,In both species radioactive compounds were eliminated from blood with half-lives ranging from 5.6 h to 7.4 h.,"Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816873/),h,5.6,157577,DB00575,Clonidine
,3816873,half-lives,In both species radioactive compounds were eliminated from blood with half-lives ranging from 5.6 h to 7.4 h.,"Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816873/),h,7.4,157578,DB00575,Clonidine
,3816873,Total excretion,Total excretion was 85.1-101.3% of radioactivity given and was complete 3-4 days after [14C]alinidine administration.,"Blood level, distribution, metabolite pattern and excretion of [14C]alinidine in mice and rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816873/),%,85.1-101.3,157579,DB00575,Clonidine
,14508316,V1,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,14.4,157827,DB00575,Clonidine
,14508316,V2,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,36.4,157828,DB00575,Clonidine
,14508316,V3,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),l,169,157829,DB00575,Clonidine
,14508316,Cl1,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],0.82,157830,DB00575,Clonidine
,14508316,Cl2,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],2.31,157831,DB00575,Clonidine
,14508316,Cl3,"The model parameters were as follows: V1, 14.4 l; V2, 36.4 l; V3, 169 l; Cl1, 0.82 l. min-1; Cl2, 2.31 l x min-1; Cl3, 1.35 l x min-1.",Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508316/),[l] / [min],1.35,157832,DB00575,Clonidine
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00575,Clonidine
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00575,Clonidine
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00575,Clonidine
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00575,Clonidine
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00575,Clonidine
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00575,Clonidine
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00575,Clonidine
,17618427,IC(50),Tolfenamic acid strongly inhibited phenacetin-O-deethylation in vitro (IC(50) 1.8 microM without albumin).,Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618427/),μM,1.8,164396,DB00575,Clonidine
exceeded,17618427,IC(50),Albumin decreased its inhibitory effect in a concentration-dependent manner; the IC(50) exceeded 100 microM with 10 mg/ml of albumin.,Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618427/),μM,100,164397,DB00575,Clonidine
,2754298,delivery efficiency,The delivery efficiency of the rods was 65 - 71%.,Ocular biodistribution of clonidine after topical application with ophthalmic rods or solution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2754298/),%,65 - 71,164450,DB00575,Clonidine
,6176801,half-lives,"The plasma concentration after the intravenous injection declined at least biexponentially with time, with mean half-lives of 0.6 +/- 0.15 h and 3.9 +/- 0.28 h for the distribution and the elimination phase, respectively.",Pharmacokinetic and pharmacodynamic properties of alinidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176801/),h,0.6,168579,DB00575,Clonidine
,6176801,half-lives,"The plasma concentration after the intravenous injection declined at least biexponentially with time, with mean half-lives of 0.6 +/- 0.15 h and 3.9 +/- 0.28 h for the distribution and the elimination phase, respectively.",Pharmacokinetic and pharmacodynamic properties of alinidine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176801/),h,3.9,168580,DB00575,Clonidine
,6176801,total clearance,The mean total clearance amounted to 40.3 +/- 8.9 L/h and the renal clearance to 33.6 +/- 12.3 L/h.,Pharmacokinetic and pharmacodynamic properties of alinidine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176801/),[l] / [h],40.3,168581,DB00575,Clonidine
,6176801,renal clearance,The mean total clearance amounted to 40.3 +/- 8.9 L/h and the renal clearance to 33.6 +/- 12.3 L/h.,Pharmacokinetic and pharmacodynamic properties of alinidine in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176801/),[l] / [h],33.6,168582,DB00575,Clonidine
,6176801,bioavailability,The bioavailability following oral administration was nearly complete (0.92 +/- 0.06).,Pharmacokinetic and pharmacodynamic properties of alinidine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6176801/),,0.92,168583,DB00575,Clonidine
,15197439,plasma concentrations,"Using a dose of 3-5 microg/kg every 8 h, plasma concentrations appeared to plateau at approximately 41 h giving a mean value of 1.38 ng/ml (95% confidence interval 1.0-1.8).",Use of oral clonidine for sedation in ventilated paediatric intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197439/),,1,168584,DB00575,Clonidine
,7205625,peak blood ethanol concentration,The mean peak blood ethanol concentration was 3.36 +/- 0.14 mg/ml.,Ethanol and functional tolerance: interactions with pimozide and clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205625/),[mg] / [ml],3.36,170430,DB00575,Clonidine
,7205625,rate of clearance,The rate of clearance of ethanol from blood was found to be 0.34 +/- 0.01 mg/ml/hr in ethanol vapor-treated and control animals when ethanol was administered acutely 48 hr after the inhalation period.,Ethanol and functional tolerance: interactions with pimozide and clonidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205625/),[mg] / [h·ml],0.34,170431,DB00575,Clonidine
,23167288,Tabs,"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,0.15,177557,DB00575,Clonidine
,23167288,Tabs(LATE),"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,2.34,177558,DB00575,Clonidine
,23167288,volume of distribution,The population parameter estimate for volume of distribution was 157 l 70 kg(-1).,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·kg],157,177559,DB00575,Clonidine
,23167288,Clearance,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],6.5,177560,DB00575,Clonidine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),month,1.6,177561,DB00575,Clonidine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],18.5,177562,DB00575,Clonidine
,15951325,arterial concentrations,"The groups had comparable mean (95% CI) arterial concentrations of propofol, 4.8 (3.5-6.1) microg ml(-1) in the patients given clonidine, and 4.6 (3.4-5.7) microg ml(-1) in the patients given placebo (P=0.81).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],4.8,178440,DB00575,Clonidine
,15951325,arterial concentrations,"The groups had comparable mean (95% CI) arterial concentrations of propofol, 4.8 (3.5-6.1) microg ml(-1) in the patients given clonidine, and 4.6 (3.4-5.7) microg ml(-1) in the patients given placebo (P=0.81).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],4.6,178441,DB00575,Clonidine
,15951325,plasma concentration,"However, the average plasma concentration predicted by the target-controlled infusion was less in the clonidine group [3.2 (2.9-3.5)] than in the group given placebo [3.6 (3.3-3.9)] microg ml(-1) (P<0.05).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],3.2,178442,DB00575,Clonidine
,15951325,plasma concentration,"However, the average plasma concentration predicted by the target-controlled infusion was less in the clonidine group [3.2 (2.9-3.5)] than in the group given placebo [3.6 (3.3-3.9)] microg ml(-1) (P<0.05).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],3.6,178443,DB00575,Clonidine
,7198476,minima,2. the steady-state levels of the plasma or blood concentrations being reached on the 2nd (clonidine) and on the 5th day (chlorthalidone) were adjusted subsequently in therapeutically relevant ranges ranging between minima and maxima of 0.2 and 0.6 ng/ml (clonidine) and between 2.4 and 2.6 microgram/ml (chlorthalidone) respectively.,[Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198476/),[ng] / [ml],0.2,178894,DB00575,Clonidine
,7198476,minima,2. the steady-state levels of the plasma or blood concentrations being reached on the 2nd (clonidine) and on the 5th day (chlorthalidone) were adjusted subsequently in therapeutically relevant ranges ranging between minima and maxima of 0.2 and 0.6 ng/ml (clonidine) and between 2.4 and 2.6 microgram/ml (chlorthalidone) respectively.,[Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198476/),[ng] / [ml],0,178895,DB00575,Clonidine
,7198476,maxima,2. the steady-state levels of the plasma or blood concentrations being reached on the 2nd (clonidine) and on the 5th day (chlorthalidone) were adjusted subsequently in therapeutically relevant ranges ranging between minima and maxima of 0.2 and 0.6 ng/ml (clonidine) and between 2.4 and 2.6 microgram/ml (chlorthalidone) respectively.,[Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198476/),[ng] / [ml],0.2,178896,DB00575,Clonidine
,7198476,maxima,2. the steady-state levels of the plasma or blood concentrations being reached on the 2nd (clonidine) and on the 5th day (chlorthalidone) were adjusted subsequently in therapeutically relevant ranges ranging between minima and maxima of 0.2 and 0.6 ng/ml (clonidine) and between 2.4 and 2.6 microgram/ml (chlorthalidone) respectively.,[Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198476/),[ng] / [ml],0,178897,DB00575,Clonidine
,7198476,maxima,2. the steady-state levels of the plasma or blood concentrations being reached on the 2nd (clonidine) and on the 5th day (chlorthalidone) were adjusted subsequently in therapeutically relevant ranges ranging between minima and maxima of 0.2 and 0.6 ng/ml (clonidine) and between 2.4 and 2.6 microgram/ml (chlorthalidone) respectively.,[Pharmacokinetics of clonidine and chlorthalidone following subacute administration of a fixed combination compared with a sustained release formulation of clonidine alone (author's transl)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7198476/),[μg] / [ml],2.4 and 2.6,178898,DB00575,Clonidine
,15338881,flow-rate,"The mobile phase, consisting of acetonitrile/ammonium hydrogen carbonate solution, was maintained to a flow-rate of 0.2 mL x min(-1) and the linear gradient elution was adopted.",[Determination of clonidine in rabbit plasma by HPLC-MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338881/),[ml] / [min],0.2,179392,DB00575,Clonidine
,15338881,m/z,Mass spectrum was obtained by using electrospray ionization interface and the m/z of SIM was 230.,[Determination of clonidine in rabbit plasma by HPLC-MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338881/),,230,179393,DB00575,Clonidine
,15338881,Cmax,"The Cmax, AUC0-t, and Tmax value of the pharmacokinetics parameter were (27 +/- 9) microg x L(-1), (5,352 +/- 1,121) microg x L(-1), (79 +/- 17) h.",[Determination of clonidine in rabbit plasma by HPLC-MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338881/),[μg] / [l],27,179394,DB00575,Clonidine
,15338881,AUC0-t,"The Cmax, AUC0-t, and Tmax value of the pharmacokinetics parameter were (27 +/- 9) microg x L(-1), (5,352 +/- 1,121) microg x L(-1), (79 +/- 17) h.",[Determination of clonidine in rabbit plasma by HPLC-MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338881/),[μg] / [l],"5,352",179395,DB00575,Clonidine
,15338881,Tmax,"The Cmax, AUC0-t, and Tmax value of the pharmacokinetics parameter were (27 +/- 9) microg x L(-1), (5,352 +/- 1,121) microg x L(-1), (79 +/- 17) h.",[Determination of clonidine in rabbit plasma by HPLC-MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15338881/),h,79,179396,DB00575,Clonidine
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,7.1,179595,DB00575,Clonidine
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,3.7,179596,DB00575,Clonidine
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,2.2,179597,DB00575,Clonidine
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,1.7,179598,DB00575,Clonidine
,7978467,Maximum plasma concentration,"Maximum plasma concentration was 0.77 ng.ml-1 (0.62-0.88), time to maximum plasma concentration 51 min (29-70), terminal half-life 12.5 h (8.7-19.5), and bioavailability 95% (73-119) (medians [95% confidence interval]).",Pharmacokinetics of clonidine after rectal administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978467/),[ng] / [ml],0.77,185917,DB00575,Clonidine
,7978467,time to maximum plasma concentration,"Maximum plasma concentration was 0.77 ng.ml-1 (0.62-0.88), time to maximum plasma concentration 51 min (29-70), terminal half-life 12.5 h (8.7-19.5), and bioavailability 95% (73-119) (medians [95% confidence interval]).",Pharmacokinetics of clonidine after rectal administration in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978467/),min,51,185918,DB00575,Clonidine
,7978467,terminal half-life,"Maximum plasma concentration was 0.77 ng.ml-1 (0.62-0.88), time to maximum plasma concentration 51 min (29-70), terminal half-life 12.5 h (8.7-19.5), and bioavailability 95% (73-119) (medians [95% confidence interval]).",Pharmacokinetics of clonidine after rectal administration in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978467/),h,12.5,185919,DB00575,Clonidine
,7978467,bioavailability,"Maximum plasma concentration was 0.77 ng.ml-1 (0.62-0.88), time to maximum plasma concentration 51 min (29-70), terminal half-life 12.5 h (8.7-19.5), and bioavailability 95% (73-119) (medians [95% confidence interval]).",Pharmacokinetics of clonidine after rectal administration in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978467/),%,95,185920,DB00575,Clonidine
,7978467,Plasma concentrations,Plasma concentrations within the adult clinically effective range (0.2-2.0 ng.ml-1) were obtained within 10 min of administration.,Pharmacokinetics of clonidine after rectal administration in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978467/),[ng] / [ml],0.2-2.0,185921,DB00575,Clonidine
,8735417,half-life of distribution,"Medetomidine was rapidly distributed, with a half-life of distribution of 4.65 +/- 0.65 min.",Single dose pharmacokinetics of medetomidine in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735417/),min,4.65,186063,DB00575,Clonidine
,8735417,apparent volume of distribution,"The apparent volume of distribution was 2.69 +/- 0.62 L/kg, while elimination half-life was 37.85 +/- 2.84 min.",Single dose pharmacokinetics of medetomidine in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735417/),[l] / [kg],2.69,186064,DB00575,Clonidine
,8735417,elimination half-life,"The apparent volume of distribution was 2.69 +/- 0.62 L/kg, while elimination half-life was 37.85 +/- 2.84 min.",Single dose pharmacokinetics of medetomidine in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735417/),min,37.85,186065,DB00575,Clonidine
,8735417,Total body clearance,Total body clearance varied between 16.29 and 151.81 mL/min.kg.,Single dose pharmacokinetics of medetomidine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735417/),[ml] / [kg·min],16.29 and,186066,DB00575,Clonidine
,8735417,Total body clearance,Total body clearance varied between 16.29 and 151.81 mL/min.kg.,Single dose pharmacokinetics of medetomidine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735417/),[ml] / [kg·min],151,186067,DB00575,Clonidine
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.5,187837,DB00575,Clonidine
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.8,187838,DB00575,Clonidine
,7619663,critical flicker fusion threshold,"4. Only buspirone reduced total reaction time and increased critical flicker fusion threshold measured 12 h after the evening dose and these effects were correlated with the residual plasma 1PP concentration which was higher on buspirone than on ipsapirone (2.76 micrograms l-1, 95% CI:1.3-4.22 vs 0.65 microgram l-1, 95% CI: 0.32-0.98, P = 0.006).",Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),[μg] / [l],2.76,188197,DB00575,Clonidine
,7619663,AUC ipsapirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,6.45,188198,DB00575,Clonidine
,7619663,AUC buspirone/AUC 1PP ratio,The AUC ipsapirone/AUC 1PP ratio was 6.45 and the AUC buspirone/AUC 1PP ratio was 0.076.,Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7619663/),,0.076,188199,DB00575,Clonidine
,12649305,binding Ki,"The H3-receptor binding Ki values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),nM,1.9,191563,DB00575,Clonidine
,12649305,binding Ki,"The H3-receptor binding Ki values for SCH 79687 were 1.9 and 13 nM in the rat and guinea pig (GP), respectively.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),nM,13,191564,DB00575,Clonidine
greater,12649305,Ki,The Ki values for SCH 79687 at histamine H1 and H2 receptors were greater than 1 microM.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μM,1,191565,DB00575,Clonidine
,12649305,pA2,The pA2 value for SCH 79687 in the GP ileum electrical field-stimulated (EFS) contraction was 9.6 +/- 0.3.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,9.6,191566,DB00575,Clonidine
,12649305,pKb,Similar H3 antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pKb = 9.4 +/- 0.3 and 10.1 +/- 0.4).,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,9.4,191567,DB00575,Clonidine
,12649305,pKb,Similar H3 antagonist activity was observed in the EFS cryopreserved and fresh tissue isolated human saphenous vein (HSV) assays (pKb = 9.4 +/- 0.3 and 10.1 +/- 0.4).,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),,10.1,191568,DB00575,Clonidine
,12649305,ED50,SCH 79687 (ED50 = 0.3 mg/kg i.v.) attenuated (R)-alpha-methylhistamine inhibition of sympathetic hypertensive responses in the GP.,"Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),[mg] / [kg],0.3,191569,DB00575,Clonidine
greater,12649305,plasma Cmax,"In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma Cmax and area under the curve values greater than 1.5 and 12.1 microg.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μg,1.5,191570,DB00575,Clonidine
greater,12649305,area under the curve,"In pharmacokinetic studies, oral dosing with SCH 79687 in the rat (10 mg/kg) and monkey (3 mg/kg) achieved plasma Cmax and area under the curve values greater than 1.5 and 12.1 microg.","Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649305/),μg,12.1,191571,DB00575,Clonidine
,7093113,Cmax,"2 After acute oral administration the following values were obtained; Cmax -- 166.5 +/- 18.5 ng/ml at 1.8 +/- 0.7 h (mean +/- s.d., n = 5); AUC -- 1122.9 ng ml-1 h; VdSS -- 190.71 and T1/2 -- 4.2 h, and after i.v. administration: AUC -- 1046.7 ng ml-1 h; VdSS -- 190.71 and T1/2 4.2 h.",Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],166.5,192455,DB00575,Clonidine
,7093113,AUC,"2 After acute oral administration the following values were obtained; Cmax -- 166.5 +/- 18.5 ng/ml at 1.8 +/- 0.7 h (mean +/- s.d., n = 5); AUC -- 1122.9 ng ml-1 h; VdSS -- 190.71 and T1/2 -- 4.2 h, and after i.v. administration: AUC -- 1046.7 ng ml-1 h; VdSS -- 190.71 and T1/2 4.2 h.",Alinidine pharmacokinetics following acute and chronic dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[h·ng] / [ml],1122.9,192456,DB00575,Clonidine
,7093113,VdSS,"2 After acute oral administration the following values were obtained; Cmax -- 166.5 +/- 18.5 ng/ml at 1.8 +/- 0.7 h (mean +/- s.d., n = 5); AUC -- 1122.9 ng ml-1 h; VdSS -- 190.71 and T1/2 -- 4.2 h, and after i.v. administration: AUC -- 1046.7 ng ml-1 h; VdSS -- 190.71 and T1/2 4.2 h.",Alinidine pharmacokinetics following acute and chronic dosing. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),h,190.71,192457,DB00575,Clonidine
,7093113,T1/2,"2 After acute oral administration the following values were obtained; Cmax -- 166.5 +/- 18.5 ng/ml at 1.8 +/- 0.7 h (mean +/- s.d., n = 5); AUC -- 1122.9 ng ml-1 h; VdSS -- 190.71 and T1/2 -- 4.2 h, and after i.v. administration: AUC -- 1046.7 ng ml-1 h; VdSS -- 190.71 and T1/2 4.2 h.",Alinidine pharmacokinetics following acute and chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),h,4.2,192458,DB00575,Clonidine
,7093113,AUC,"2 After acute oral administration the following values were obtained; Cmax -- 166.5 +/- 18.5 ng/ml at 1.8 +/- 0.7 h (mean +/- s.d., n = 5); AUC -- 1122.9 ng ml-1 h; VdSS -- 190.71 and T1/2 -- 4.2 h, and after i.v. administration: AUC -- 1046.7 ng ml-1 h; VdSS -- 190.71 and T1/2 4.2 h.",Alinidine pharmacokinetics following acute and chronic dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[h·ng] / [ml],1046.7,192459,DB00575,Clonidine
,7093113,VdSS,"2 After acute oral administration the following values were obtained; Cmax -- 166.5 +/- 18.5 ng/ml at 1.8 +/- 0.7 h (mean +/- s.d., n = 5); AUC -- 1122.9 ng ml-1 h; VdSS -- 190.71 and T1/2 -- 4.2 h, and after i.v. administration: AUC -- 1046.7 ng ml-1 h; VdSS -- 190.71 and T1/2 4.2 h.",Alinidine pharmacokinetics following acute and chronic dosing. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),,190.71,192460,DB00575,Clonidine
,7093113,Cmax,3 Clonidine was identified in plasma and urine samples following oral and i.v. administration; clonidine Cmax was 0.26 +/- 0.06 ng/ml at 8.4 +/- 2.2 h and 0.5 +/- 0.2 ng/ml at 4.8 +/- 2.5 following oral and i.v. alinidine respectively.,Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],0.26,192461,DB00575,Clonidine
,7093113,Cmax,3 Clonidine was identified in plasma and urine samples following oral and i.v. administration; clonidine Cmax was 0.26 +/- 0.06 ng/ml at 8.4 +/- 2.2 h and 0.5 +/- 0.2 ng/ml at 4.8 +/- 2.5 following oral and i.v. alinidine respectively.,Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],0.5,192462,DB00575,Clonidine
,7093113,peak,"4 During administration of alinidine 40 mg daily for 8 days, peak and trough plasma levels reached steady state after day 2 (223.1 +/- 123.9 and 9.03 +/- 6.7 ng/ml respectively).",Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],223.1,192463,DB00575,Clonidine
,7093113,trough plasma levels,"4 During administration of alinidine 40 mg daily for 8 days, peak and trough plasma levels reached steady state after day 2 (223.1 +/- 123.9 and 9.03 +/- 6.7 ng/ml respectively).",Alinidine pharmacokinetics following acute and chronic dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],9.03,192464,DB00575,Clonidine
,7093113,peak,"During alinidine 40 mg twice daily for 8 days peak and trough plasma levels on day 2 were 356.2 +/- 92.0 and 80.0 +/- 35.8 ng/ml respectively, these levels did not change (P greater than 0.05) between days 2 and 8.",Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],356.2,192465,DB00575,Clonidine
,7093113,trough plasma levels,"During alinidine 40 mg twice daily for 8 days peak and trough plasma levels on day 2 were 356.2 +/- 92.0 and 80.0 +/- 35.8 ng/ml respectively, these levels did not change (P greater than 0.05) between days 2 and 8.",Alinidine pharmacokinetics following acute and chronic dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],80.0,192466,DB00575,Clonidine
,7093113,plasma concentration,5 Clonidine plasma concentration following alinidine 40 mg daily and twice daily were 0.47 +/- 0.18 and 0.84 +/- 0.21 ng/ml respectively 2 h after administration on day 2 and did not change (P less than 0.05) between days 2-8.,Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],0.47,192467,DB00575,Clonidine
,7093113,plasma concentration,5 Clonidine plasma concentration following alinidine 40 mg daily and twice daily were 0.47 +/- 0.18 and 0.84 +/- 0.21 ng/ml respectively 2 h after administration on day 2 and did not change (P less than 0.05) between days 2-8.,Alinidine pharmacokinetics following acute and chronic dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093113/),[ng] / [ml],0.84,192468,DB00575,Clonidine
,27141268,Limit of Quantification (LOQ),The Limit of Quantification (LOQ) was 0.01 ng/ml.,LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [ml],0.01,194523,DB00575,Clonidine
,27141268,Cmax,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [ml],6.16,194524,DB00575,Clonidine
,27141268,Tmax,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [ml],6.21,194525,DB00575,Clonidine
,27141268,Tmax,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),h,30.12,194526,DB00575,Clonidine
,27141268,AUC0-t,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [ml],6.21,194527,DB00575,Clonidine
,27141268,AUC0-t,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),h,30.12,194528,DB00575,Clonidine
,27141268,AUC0-∞,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [h·ml],290.37,194529,DB00575,Clonidine
,27141268,AUC0-∞,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [h·ml],293.39,194530,DB00575,Clonidine
,27141268,AUC0-∞,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [h·ml],350.17,194531,DB00575,Clonidine
,27141268,AUC0-∞,"The mean (SD) Cmax, Tmax, AUC0-t and AUC0-∞ values after administration of the test and reference formulations, respectively, were in this manner: 6.16 (0.32) versus 6.21 (0.07) ng/ml, 30.12 (0.86) versus 30.13 (0.73) hr, 290.37 (1.13) versus 293.39 (1.22) ng/ml/hr, and 350.17 (1.98) versus 352.96 (1.67) ng/ml/hr.",LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),[ng] / [h·ml],352.96,194532,DB00575,Clonidine
,27141268,t1/2,The mean (SD) t1/2 was 120.12 (1.90) hr for the test formulation and 120.96 (1.54) hr for the reference formulation.,LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),h,120.12,194533,DB00575,Clonidine
,27141268,t1/2,The mean (SD) t1/2 was 120.12 (1.90) hr for the test formulation and 120.96 (1.54) hr for the reference formulation.,LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27141268/),h,120.96,194534,DB00575,Clonidine
,29566073,AUC 0-t,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],6655.64,196390,DB00575,Clonidine
,29566073,AUC 0-t,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],6538.99,196391,DB00575,Clonidine
,29566073,Cmax,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],436.98,196392,DB00575,Clonidine
,29566073,Cmax,The pharmacokinetic study exhibited prompt absorption of MLX with better AUC 0-t (6655.64 ng/ml*h vs 6538.99 ng/ml*h) and Cmax (436.98 ng/ml vs 411.33 ng/ml) from oral dispersion.,Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],411.33,196393,DB00575,Clonidine
,29566073,half-life,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),h,9.91,196394,DB00575,Clonidine
,29566073,half-life,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),h,2.51,196395,DB00575,Clonidine
,29566073,AUC 0-t,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],1043.4,196396,DB00575,Clonidine
,29566073,AUC 0-t,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [h·ml],149.1,196397,DB00575,Clonidine
,29566073,Cmax,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],91.92,196398,DB00575,Clonidine
,29566073,Cmax,"Similarly buccal films has shown enhanced half-life (9.91hr vs 2.51 hr), AUC 0-t (1043.4 ng/ml*h vs 149.1 ng/ml*h) and Cmax (91.92 ng/ml vs 42.29 ng/ml) from oral solution.",Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29566073/),[ng] / [ml],42.29,196399,DB00575,Clonidine
,1623908,t1/2s,The t1/2s for effect compartment equilibration were 29 and 42 min for clonidine + naloxone and clonidine.,"Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623908/),min,29,199972,DB00575,Clonidine
,1623908,t1/2s,The t1/2s for effect compartment equilibration were 29 and 42 min for clonidine + naloxone and clonidine.,"Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623908/),min,42,199973,DB00575,Clonidine
,16810637,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Quantification of tizanidine in human plasma by liquid chromatography coupled to tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16810637/),min,2.5,203985,DB00575,Clonidine
,19116263,apparent oral clearance,"Clonidine apparent oral clearance was found to be 440 +/- 168 ml/min during pregnancy compared with 245 +/- 72 ml/min as previously reported in nonpregnant subjects (p < 0.0001) (Cunningham et al., 1994).",Clonidine pharmacokinetics in pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19116263/),[ml] / [min],440,204870,DB00575,Clonidine
,19116263,apparent oral clearance,"Clonidine apparent oral clearance was found to be 440 +/- 168 ml/min during pregnancy compared with 245 +/- 72 ml/min as previously reported in nonpregnant subjects (p < 0.0001) (Cunningham et al., 1994).",Clonidine pharmacokinetics in pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19116263/),[ml] / [min],245,204871,DB00575,Clonidine
,19116263,concentration ratios,Umbilical cord to maternal plasma clonidine concentration ratios were 1.0 +/- 0.1 (arterial) and 1.0 +/- 0.1 (venous).,Clonidine pharmacokinetics in pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19116263/),,1.0,204872,DB00575,Clonidine
,687501,distribution phase,2 Clonidine disposition could be described by a two compartment open model and pharmacokinetic parameters show a rapid distribution phase of 20--30 min and a mean plasma clearance of 4.6 ml min-1 kg-1 (75--200 microgram).,Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/687501/),min,20,208095,DB00575,Clonidine
,687501,plasma clearance,2 Clonidine disposition could be described by a two compartment open model and pharmacokinetic parameters show a rapid distribution phase of 20--30 min and a mean plasma clearance of 4.6 ml min-1 kg-1 (75--200 microgram).,Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/687501/),[ml] / [kg·min],4.6,208096,DB00575,Clonidine
,687501,half-life of the beta-phase,The half-life of the beta-phase was found to be in the range of 7.4--11.4 h.,Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/687501/),h,7.4--11.4,208097,DB00575,Clonidine
,19371738,K(m),"A kinetic study showed that cefditoren transport by PEPT1 in Caco-2 cells had K(m) and V(max) values of 0.94+/-0.11 mM and 0.49+/-0.09 nmol/mg protein/5 min, respectively.",PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371738/),mM,0.94,208750,DB00575,Clonidine
,19371738,V(max),"A kinetic study showed that cefditoren transport by PEPT1 in Caco-2 cells had K(m) and V(max) values of 0.94+/-0.11 mM and 0.49+/-0.09 nmol/mg protein/5 min, respectively.",PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371738/),[nM] / [·5·mg·min],0.49,208751,DB00575,Clonidine
,19371738,biliary,"In vivo, biliary and urinary excretions over 6 h were an average of 34% and 4% of the administered cefditoren respectively.",PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371738/),%,34,208752,DB00575,Clonidine
,19371738,urinary excretions,"In vivo, biliary and urinary excretions over 6 h were an average of 34% and 4% of the administered cefditoren respectively.",PEPT1 involved in the uptake and transepithelial transport of cefditoren in vivo and in vitro. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19371738/),%,4,208753,DB00575,Clonidine
,7332729,plasma clearance,"2 With increasing i.v. doses the rate constants (alpha, beta) decreased and the plasma clearance was reduced by 74% (9.94--2.61 ml min-1 kg-1) indicating dose-dependent kinetics.",Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332729/),[ml] / [kg·min],9.94,211389,DB00575,Clonidine
,7332729,bioavailability,The bioavailability was 90%.,Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332729/),%,90,211390,DB00575,Clonidine
,7332729,plasma clearance,The plasma clearance increased (7.18 ml min-1 kg-1) compared to the corresponding single dose (4.17 ml min-1 kg-1).,Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332729/),[ml] / [kg·min],7.18,211391,DB00575,Clonidine
,7332729,plasma clearance,The plasma clearance increased (7.18 ml min-1 kg-1) compared to the corresponding single dose (4.17 ml min-1 kg-1).,Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332729/),[ml] / [kg·min],4.17,211392,DB00575,Clonidine
,7332729,bioavaila,The latter change was probably caused by the decrease in bioavailability to about 65%.,Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7332729/),,65,211393,DB00575,Clonidine
,598422,Peak plasma clonidine concentration,Peak plasma clonidine concentration (1.34 +/- 0.28 ng/ml) and plasma half-life (10.0 +/- 0.8 h) were similar to normotensives.,Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598422/),[ng] / [ml],1.34,214384,DB00575,Clonidine
,598422,plasma half-life,Peak plasma clonidine concentration (1.34 +/- 0.28 ng/ml) and plasma half-life (10.0 +/- 0.8 h) were similar to normotensives.,Pharmacokinetic and concentration-effect relationships of clonidine in essential hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598422/),h,10.0,214385,DB00575,Clonidine
,582739,detection limit,The detection limit of the presented radioimmunoassay for clonidine is 0.1 ng/ml.,A newly developed precise and sensitive radioimmunoassay for clonidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582739/),[ng] / [ml],0.1,219279,DB00575,Clonidine
,582739,maximal clonidine concentration,With the radioimmunoassay applied in pharmacokinetic studies a maximal clonidine concentration in blood plasma of healthy human volunteers was determined to 0.6 ng/ml 1.5 h after oral administration of 150 micrograms.,A newly developed precise and sensitive radioimmunoassay for clonidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582739/),[ng] / [ml],0.6,219280,DB00575,Clonidine
,23735833,Peak clonidine concentrations,Peak clonidine concentrations of 0.846 ± 0.288 ng/ml were reached after 1 h.,Pharmacokinetics and pharmacodynamics of orally administered clonidine: a model-based approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735833/),[ng] / [ml],0.846,219950,DB00575,Clonidine
,9385489,total body clearance,"Mean (+/- SD) plasma clonidine concentration and calculated total body clearance after 7 days of infusion (respectively, 2.19 +/- 1.17 ng/mL, n = 24; 279 +/- 184 mL/min, n = 27) were comparable to those following 14 days of infusion (2.50 +/- 1.51 ng/mL, n = 19; 272 +/- 163 mL/min, n = 21).",Plasma concentrations and disposition of clonidine following a constant 14-day epidural infusion in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9385489/),[ml] / [min],279,220742,DB00575,Clonidine
,9385489,total body clearance,"Mean (+/- SD) plasma clonidine concentration and calculated total body clearance after 7 days of infusion (respectively, 2.19 +/- 1.17 ng/mL, n = 24; 279 +/- 184 mL/min, n = 27) were comparable to those following 14 days of infusion (2.50 +/- 1.51 ng/mL, n = 19; 272 +/- 163 mL/min, n = 21).",Plasma concentrations and disposition of clonidine following a constant 14-day epidural infusion in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9385489/),[ml] / [min],272,220743,DB00575,Clonidine
,17350525,maximum plasma concentration (Cpmax),There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.51,231928,DB00575,Clonidine
,17350525,time to maximum concentration tCpmax,There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231929,DB00575,Clonidine
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.62,231930,DB00575,Clonidine
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.79,231931,DB00575,Clonidine
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231932,DB00575,Clonidine
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,22.5,231933,DB00575,Clonidine
,17350525,Cpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.47,231934,DB00575,Clonidine
,17350525,tCpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),h,24,231935,DB00575,Clonidine
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.72,231936,DB00575,Clonidine
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],1.74,231937,DB00575,Clonidine
,2178493,Onset of anal,"Onset of analgesia was similar (within 15 min of injection), but duration tended to be longer after epidural than intramuscular administration (208 +/- 87 min vs. 168 +/- 95 min, mean +/- SD, P greater than 0.05).",Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178493/),min,208,236022,DB00575,Clonidine
,2178493,duration,"Onset of analgesia was similar (within 15 min of injection), but duration tended to be longer after epidural than intramuscular administration (208 +/- 87 min vs. 168 +/- 95 min, mean +/- SD, P greater than 0.05).",Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178493/),min,208,236023,DB00575,Clonidine
,2178493,duration,"Onset of analgesia was similar (within 15 min of injection), but duration tended to be longer after epidural than intramuscular administration (208 +/- 87 min vs. 168 +/- 95 min, mean +/- SD, P greater than 0.05).",Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178493/),min,168,236024,DB00575,Clonidine
,2178493,peak plasma clonidine concentration,The peak plasma clonidine concentration after EP injection was 0.82 +/- 0.22 ng/ml and 1.02 +/- 0.76 ng/ml after IM injection.,Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178493/),[ng] / [ml],0.82,236025,DB00575,Clonidine
,2178493,peak plasma clonidine concentration,The peak plasma clonidine concentration after EP injection was 0.82 +/- 0.22 ng/ml and 1.02 +/- 0.76 ng/ml after IM injection.,Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2178493/),[ng] / [ml],1.02,236026,DB00575,Clonidine
,2600869,plasma half-life,The plasma half-life was 2.7 +/- 0.06 hours.,Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2600869/),h,2.7,236104,DB00575,Clonidine
,6428208,ratio of maximum to minimum plasma levels,The ratio of maximum to minimum plasma levels during a dosing interval was 2 for oral Catapres and approximately 1 for Catapres -TTS.,Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428208/),,2,242206,DB00575,Clonidine
,6428208,ratio of maximum to minimum plasma levels,The ratio of maximum to minimum plasma levels during a dosing interval was 2 for oral Catapres and approximately 1 for Catapres -TTS.,Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428208/),,1,242207,DB00575,Clonidine
,7605757,duration of,"The duration of labor after epidural administration was prolonged in group B + C patients compared to group B (282 +/- 43 minutes and 169 +/- 26 minutes, respectively, P < .05).",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),min,282,250891,DB00575,Clonidine
,7605757,duration of,"The duration of labor after epidural administration was prolonged in group B + C patients compared to group B (282 +/- 43 minutes and 169 +/- 26 minutes, respectively, P < .05).",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),min,169,250892,DB00575,Clonidine
,7605757,concentrations,"Plasma clonidine concentrations were, respectively, 0.31 +/- 0.16 ng/mL 60 minutes after the first injection and 0.62 +/- 0.13 ng/mL at birth in mothers while plasma umbilical cord concentrations were 0.56 +/- 0.12 ng/mL.",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),[ng] / [ml],0.31,250893,DB00575,Clonidine
,7605757,concentrations,"Plasma clonidine concentrations were, respectively, 0.31 +/- 0.16 ng/mL 60 minutes after the first injection and 0.62 +/- 0.13 ng/mL at birth in mothers while plasma umbilical cord concentrations were 0.56 +/- 0.12 ng/mL.",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),[ng] / [ml],0.56,250894,DB00575,Clonidine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,8.3,251826,DB00575,Clonidine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,2.1,251827,DB00575,Clonidine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,4.0,251828,DB00575,Clonidine
,1587960,Tmax,The Tmax of the slow-release formulation was significantly later than for the conventional formulation after both acute (8.3 +/- 6 hr vs. 2.1 +/- 2 hr) and chronic administration (4.0 +/- 3 hr vs. 2.5 +/- 2 hr).,Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,2.5,251829,DB00575,Clonidine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.42,251830,DB00575,Clonidine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.70,251831,DB00575,Clonidine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.99,251832,DB00575,Clonidine
,1587960,Cmax,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [ml],0.84,251833,DB00575,Clonidine
,1587960,AUC,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [h·ml],16.2,251834,DB00575,Clonidine
,1587960,AUC,"The Cmax was approximately 60% lower for the slow-release formulation (1 x 150 micrograms; 0.42 +/- 0.09 ng/mL) compared with the conventional formulation (2 x 75 micrograms; 0.70 +/- 0.12 ng/mL) after acute administration, whereas in the steady state, in which the dose of the conventional preparation was halved (75 micrograms), the Cmax values were comparable: 1 x 150 micrograms-0.99 +/- 0.27 ng/mL, 1 x 75 micrograms-0.84 +/- 0.20 ng/mL and the dose-normalized interdose AUC were identical for the conventional (16.2 +/- 4.3 ng/mL.hr) and slow release (16.6 +/- 5.3 ng/mL.hr) products.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),[ng] / [h·ml],16.6,251835,DB00575,Clonidine
exceeded,1587960,T1/2,"T1/2 values for the conventional formulation of clonidine exceeded 20 hours in all but one subject and were considerably longer than those in previous reports, including those of the authors, in which a less sensitive assay was used.",Pharmacokinetic comparison of a slow-release clonidine with a conventional formulation after acute and chronic administration in hypertensives. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587960/),h,20,251836,DB00575,Clonidine
,7912045,Tmax,"Dexmedetomidine absorption in CSF after epidural injection was rapid (Tmax = 5-20 min), although pharmacokinetic modeling suggested a biphasic absorption process.",Pharmacokinetics and pharmacodynamics of intraspinal dexmedetomidine in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7912045/),min,5-20,255670,DB00575,Clonidine
,20735802,bioavailability,The bioavailability of clonidine given orally in adults is 75-100% but is unknown in children.,Oral bioavailability of clonidine in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),%,75-100,259188,DB00575,Clonidine
,20735802,absorption half-life (Tabs),"Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1).",Oral bioavailability of clonidine in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),h,0.45,259189,DB00575,Clonidine
,20735802,absorption lag time (Tlag),"Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1).",Oral bioavailability of clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),h,0.148,259190,DB00575,Clonidine
,20735802,Clearance (CL),"Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1).",Oral bioavailability of clonidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),[l] / [70·h·kg],17.9,259191,DB00575,Clonidine
,20735802,compartment clearance (Q),"Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1).",Oral bioavailability of clonidine in children. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),[l] / [70·h·kg],121,259192,DB00575,Clonidine
,20735802,central volume (V1),"Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1).",Oral bioavailability of clonidine in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),[l] / [70·kg],81.2,259193,DB00575,Clonidine
,20735802,peripheral volume of distribution (V2),"Population parameter estimates (CV%; 95% CI), standardized to a 70-kg person, were absorption half-life (Tabs), 0.45 (85.1; 0.221-0.884) h, absorption lag time (Tlag), 0.148 (91.2; 0.002-0.316) h, Clearance (CL) 17.9 (30.3; 16-20.3) l·h(-1) per 70 kg, between compartment clearance (Q) 121 (44.3; 80.1-165) l·h(-1) per 70 kg, central volume (V1) 81.2 (71.5; 60.7-105) l·70 kg(-1), peripheral volume of distribution (V2) 113 (33.9; 91-131) l·70 kg(-1).",Oral bioavailability of clonidine in children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),[l] / [70·kg],113,259194,DB00575,Clonidine
,20735802,oral bioavailability,"The oral bioavailability was 55.4% (CV 6.4%; 95% CI 0.469, 0.654).",Oral bioavailability of clonidine in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),%,55.4,259195,DB00575,Clonidine
,20735802,T(max),"Clonidine administered with an apple fruit drink displays a variable and relatively slow absorption after oral administration (T(max) 1.04 h, C(max) 0.77 mcg·l(-1)).",Oral bioavailability of clonidine in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),h,1.04,259196,DB00575,Clonidine
,20735802,C(max),"Clonidine administered with an apple fruit drink displays a variable and relatively slow absorption after oral administration (T(max) 1.04 h, C(max) 0.77 mcg·l(-1)).",Oral bioavailability of clonidine in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),[mcg] / [l],0.77,259197,DB00575,Clonidine
,20735802,oral bioavailability,"The oral bioavailability was 55.4%, which is less than reported in adults.",Oral bioavailability of clonidine in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735802/),%,55.4,259198,DB00575,Clonidine
,7686916,peak,"The mean pretreatment IGF-I level (36 +/- 2 micrograms/L) was 19% of the Ecuadorian control value (190 +/- 15 micrograms/L), it achieved a peak (253 +/- 11 micrograms/L) between 2-6 h after IGF-I injection, and at 12 h it was 137 +/- 8 micrograms/L.",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[μg] / [l],253,260584,DB00575,Clonidine
,7686916,half-life,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),h,8.2,260585,DB00575,Clonidine
,7686916,half-life,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),h,9.7,260586,DB00575,Clonidine
,7686916,metabolic clearance,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg·min],0.35,260587,DB00575,Clonidine
,7686916,metabolic clearance,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg·min],0.24,260588,DB00575,Clonidine
,7686916,distribution volume,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg],183,260589,DB00575,Clonidine
,7686916,distribution volume,"There were no significant changes in the half-life (8.2 +/- 1.5 to 9.7 +/- 1.9 h) or metabolic clearance (0.35 +/- 0.1 to 0.24 +/- 0.05 mL/kg.min) between days 1 and 7; however, distribution volume increased (183 +/- 10 to 266 +/- 36 mL/kg; P < 0.03).",Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7686916/),[ml] / [kg],266,260590,DB00575,Clonidine
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],2.47,263208,DB00575,Clonidine
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],3.17,263209,DB00575,Clonidine
,15684489,half-life,"The average half-life, Tmax, Cmax and Css values of clonidine in rabbits following administration of KBD-TTS were 19.27+/-4.68 h, 52.56+/-25.77 h, 27.39+/-9.03 ng/ml, and 25.82+/-9.34 ng/ml, similar to those of Catapres-TTS, respectively.",In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684489/),h,19.27,265490,DB00575,Clonidine
,15684489,Tmax,"The average half-life, Tmax, Cmax and Css values of clonidine in rabbits following administration of KBD-TTS were 19.27+/-4.68 h, 52.56+/-25.77 h, 27.39+/-9.03 ng/ml, and 25.82+/-9.34 ng/ml, similar to those of Catapres-TTS, respectively.",In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684489/),h,52.56,265491,DB00575,Clonidine
,15684489,Cmax,"The average half-life, Tmax, Cmax and Css values of clonidine in rabbits following administration of KBD-TTS were 19.27+/-4.68 h, 52.56+/-25.77 h, 27.39+/-9.03 ng/ml, and 25.82+/-9.34 ng/ml, similar to those of Catapres-TTS, respectively.",In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684489/),h,52.56,265492,DB00575,Clonidine
,15684489,Css,"The average half-life, Tmax, Cmax and Css values of clonidine in rabbits following administration of KBD-TTS were 19.27+/-4.68 h, 52.56+/-25.77 h, 27.39+/-9.03 ng/ml, and 25.82+/-9.34 ng/ml, similar to those of Catapres-TTS, respectively.",In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15684489/),[ng] / [ml],25.82,265493,DB00575,Clonidine
,7128667,initial lag time,"Following oral administration, the drug was absorbed rapidly after an initial lag time of 19-22 min and peak levels were reached between 2.4 and 2.9 h.",Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128667/),min,19-22,266977,DB00575,Clonidine
,7128667,half-life of the elimination phase,Post-peak plasma concentration declined in a monoexponential manner and the half-life of the elimination phase ranged from 9.0 to 15.1 h.,Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128667/),h,9.0 to 15.1,266978,DB00575,Clonidine
,8068579,elimination half-life,"After oral administration the maximum concentration of moxonidine is reached in about 1 hour, and elimination half-life is 2.5 hours, prolonged by renal insufficiency.",Clinical experience with moxonidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8068579/),h,2.5,267059,DB00575,Clonidine
,18393298,time to maximum concentration,In the single dose study the average time to maximum concentration was observed at approximately 3 h for the single doses tested (1.2 mg dose and 2.0 mg).,Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),h,3,268290,DB00575,Clonidine
,18393298,elimination rates,"The average elimination rates for the 1.2 mg and the 2.0 mg doses were 0.063 and 0.065 h(-1), respectively.",Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),1/[h],0.063,268291,DB00575,Clonidine
,18393298,elimination rates,"The average elimination rates for the 1.2 mg and the 2.0 mg doses were 0.063 and 0.065 h(-1), respectively.",Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),1/[h],0.065,268292,DB00575,Clonidine
,18393298,maximum concentration,"In the multidose study, the average maximum concentration observed after the first dose of 0.4 mg was 433 ng/L and ranged from 338 to 586 ng/L.",Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),[ng] / [l],433,268293,DB00575,Clonidine
,18393298,maximum concentration,"In the multidose study, the average maximum concentration observed after the first dose of 0.4 mg was 433 ng/L and ranged from 338 to 586 ng/L.",Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),[ng] / [l],338 to 586,268294,DB00575,Clonidine
,18393298,C(max),This was slightly lower in proportion to the maximum concentration observed in the single dose study where C(max) was 1755 ng/L at the 1.2 mg dose (normalized to 585 ng/L for 0.4 mg dose) and for the 2.0 mg dose (normalized to 559 ng/L for 0.4 mg dose).,Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),[ng] / [l],1755,268295,DB00575,Clonidine
,18393298,C(max),This was slightly lower in proportion to the maximum concentration observed in the single dose study where C(max) was 1755 ng/L at the 1.2 mg dose (normalized to 585 ng/L for 0.4 mg dose) and for the 2.0 mg dose (normalized to 559 ng/L for 0.4 mg dose).,Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),[ng] / [l],585,268296,DB00575,Clonidine
,18393298,C(max),This was slightly lower in proportion to the maximum concentration observed in the single dose study where C(max) was 1755 ng/L at the 1.2 mg dose (normalized to 585 ng/L for 0.4 mg dose) and for the 2.0 mg dose (normalized to 559 ng/L for 0.4 mg dose).,Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),,559,268297,DB00575,Clonidine
,18393298,time to maximum concentration (T(max)),The average time to maximum concentration (T(max)) was 3.33 h which is comparable to values observed in the single dose study.,Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),h,3.33,268298,DB00575,Clonidine
,18393298,elimination half-life,"Steady state seems to be reached after 2 days on lofexidine, which is consistent with the lofexidine elimination half-life of approximately 11 h.",Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18393298/),h,11,268299,DB00575,Clonidine
,1071696,Plasma half-lives,2. Plasma half-lives of clonidine ranged from 6-9 to 9-4 h in five normotensive subjects.,Pharmacokinetic and pharmacological studies with clonidine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1071696/),h,6-9,271223,DB00575,Clonidine
,1071696,Plasma half-lives,2. Plasma half-lives of clonidine ranged from 6-9 to 9-4 h in five normotensive subjects.,Pharmacokinetic and pharmacological studies with clonidine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1071696/),h,9-4,271224,DB00575,Clonidine
,870272,t1/2alpha,The drug is rapidly distributed (t1/2alpha = 10.8 +/- 4.7 min) but slowly elimainated (t1/2beta = 8.5 +/- 0.9 hr).,Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870272/),min,10.8,271710,DB00575,Clonidine
,870272,t1/2beta,The drug is rapidly distributed (t1/2alpha = 10.8 +/- 4.7 min) but slowly elimainated (t1/2beta = 8.5 +/- 0.9 hr).,Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870272/),h,8.5,271711,DB00575,Clonidine
,870272,bioavailability,The bioavailability of oral clonidine in the tablets tested averaged 75.2% and 40 to 50% of the bioavailable dose is excreted unchanged in urine.,Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870272/),%,75.2,271712,DB00575,Clonidine
,870272,bioavailability,The bioavailability of oral clonidine in the tablets tested averaged 75.2% and 40 to 50% of the bioavailable dose is excreted unchanged in urine.,Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870272/),%,40 to 50,271713,DB00575,Clonidine
,870272,Renal clearance,Renal clearance of the drug showed considerable intersubject variation (1.82 +/- 0.34 ml/min/kg) and exceed the calculated glomerular filtration rate in some subjects.,Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/870272/),[ml] / [kg·min],1.82,271714,DB00575,Clonidine
,30221568,enhancement ratio (ER,The permeation parameters of the selected bilosomes were compared to the unformulated drug and it was shown that TZN-B24 exhibited the highest enhancement ratio (ER = 8.8).,Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30221568/),,8.8,272021,DB00575,Clonidine
,30221568,VS,The mathematical model used for the optimization was validated by comparing the predicted values of the EE (82.3%) and the VS (165.8 nm) with the experimental values of EE = 84.42% and of VS = 161.95 nm.,Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30221568/),,165,272022,DB00575,Clonidine
,30221568,VS,The mathematical model used for the optimization was validated by comparing the predicted values of the EE (82.3%) and the VS (165.8 nm) with the experimental values of EE = 84.42% and of VS = 161.95 nm.,Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30221568/),nm,161.95,272023,DB00575,Clonidine
,31103968,t1/2,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,2.51,274032,DB00575,Clonidine
,31103968,t1/2,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,10,274033,DB00575,Clonidine
,31103968,Cmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),[ng] / [ml],42.3,274034,DB00575,Clonidine
,31103968,Cmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),[ng] / [ml],105,274035,DB00575,Clonidine
,31103968,tmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,2,274036,DB00575,Clonidine
,31103968,tmax,"Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, Cmax from 42.3 ng/ml (SOS) to 105ng/ml and tmax from 2hrs (SOS) to 6h.",Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103968/),h,6,274037,DB00575,Clonidine
